

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/047288 A1

(51) International Patent Classification⁷: **C07D 487/04**,
A61K 31/505, A61P 31/12, C07D 487/04, 239/00, 231/00

(21) International Application Number:
PCT/GB2004/004744

(22) International Filing Date:
10 November 2004 (10.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0326168.2 10 November 2003 (10.11.2003) GB

(71) Applicant (for all designated States except US): **ARROW THERAPEUTICS LIMITED** [GB/GB]; Britannia House, 7 Trinity Street, London SE1 1DA (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TIBERGHIE**
Nathalie [FR/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB).
LUMLEY, James [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB).
REYNOLDS, Karen [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA

(GB). **ANGELL, Richard, Martyn** [GB/GB]; Arrow Therapeutics Ltd, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **MATTHEWS, Neil** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **COCKERILL, George, Stuart** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB). **BARNES, Michael, Christopher** [GB/GB]; Arrow Therapeutics Limited, Britannia House, 7 Trinity Street, London SE1 1DA (GB).


(74) Agent: **SRINIVASAN, Ravi, Chandran**; J.A. Kemp & CO, 14 South Square, Gray's Inn, London WC1R 5JJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,

[Continued on next page]

(54) Title: PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS



(I)

(57) Abstract: Pyrazolopyrimidine derivatives of formula (I), or a pharmaceutically acceptable salt thereof, are found to be active against hepatitis C infection, wherein: R₁ is C₆-C₁₀ aryl, 5- to 10- membered heteroaryl, -(C₁-C₄ alkyl)-(C₆-C₁₀ aryl) or -(C₁-C₄ alkyl)-(5- to 10- membered heteroaryl); R₂ is a C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety; and X is -NR', -NR'-CO-NR'', -NR'-L, or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C₁-C₆ alkyl group and L represents a C₁-C₆ alkylene group, the aryl, heteroaryl, heterocyclyl, and carbocyclyl moieties in the R₁ and R₂ substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl C₁-C₄alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, nitro, C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'CO₂-R'', -CO₂R'', -COR'''-NR'-CO-R''', -CONR'R'', SO₂NR'R'', SO₂R''' and -O-(CH₂)_n-R''' substituents, wherein n is from 0 to 4, each R' is the same or different and is hydrogen or C₁-C₆ alkyl, each R'' is the same or different and is hydrogen, C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, and each R''' is the same or different and is C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl, C₁-C₄ hydroxyalkyl and C₁-C₄ haloalkyl groups.



WO 2005/047288 A1



ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:


— *with international search report*

PYRAZOLOPYRIMIDINES AS ANTI - HEPATITIS C AGENTS

The present invention relates to a series of pyrazolo[3,4-*d*]pyrimidine derivatives which are useful in treating or preventing a hepatitis C infection.

5 WO 94/13677 discloses pyrazolopyrimidines as CRF antagonists. All of the compounds specifically disclosed in that document carry a trisubstituted phenyl group at the 1-position.

The present invention provides, in a first embodiment, the use of a pyrazolopyrimidine derivative of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or preventing a
10 flaviviridae infection, for example a hepatitis C infection,



wherein:

- R₁ is C₆-C₁₀ aryl, 5- to 10- membered heteroaryl, -(C₁-C₄ alkyl)-(C₆-C₁₀ aryl) or
15 -(C₁-C₄ alkyl)-(5- to 10- membered heteroaryl);
- R₂ is a C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclic ring; and
- 20 - X is -NR', -NR'-CO-NR'', -NR'-L- or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C₁-C₆ alkyl group and L represents a C₁-C₆ alkylene group,

the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from
25 halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, nitro, C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'-CO₂-R'', -CO₂R'', -COR''', -NR'-CO-R''', -CONR'R'', -SO₂NR'R'',

-SO₂R^{'''} and -O-(CH₂)_n-R^{'''} substituents, wherein n is from 0 to 4, each R['] is the same or different and is hydrogen or C₁-C₆ alkyl, each R^{''} is the same or different and is hydrogen, C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R^{'''} is the same or different and is C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl and each R^{'''} is the same or different and is C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl,

the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl, C₁-C₄ hydroxalkyl and C₁-C₄ haloalkyl groups.

Preferably, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents are unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, nitro, C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR[']-CO₂-R^{''}, -CO₂R^{''}, -COR^{'''}, -NR[']-CO-R^{'''}, -CONR[']R^{''}, -SO₂NR[']R^{''} and -SO₂R^{'''} substituents, wherein each R['] is the same or different and is hydrogen or C₁-C₆ alkyl, each R^{''} is the same or different and is hydrogen, C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl and each R^{'''} is the same or different and is C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl,

the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl, C₁-C₄ hydroxalkyl and C₁-C₄ haloalkyl groups.

For the avoidance of doubt, the orientation of the X moiety is such that the left hand side of the depicted groups are attached to the pyrazolopyrimidine ring and the right hand side of the depicted groups are attached to R₂. Thus, for example, when X is -NR[']-CO-L-, the 4- substituent on the pyrazolopyrimidine moiety is -NR[']-CO-L-R₂.

As used herein, a C₁-C₆ alkyl group or moiety is a linear or branched alkyl group or moiety containing from 1 to 6 carbon atoms, such as a C₁-C₄ alkyl group or moiety. Examples of C₁-C₄ alkyl groups and moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl and t-butyl. For the avoidance of doubt, where two alkyl moieties are present in a group, the alkyl moieties may be the same or different.

As used herein, a C₁-C₆ alkylene group or moiety is a linear or branched

alkylene group or moiety, such as a C₁-C₄ alkylene group or moiety. Examples include methylene, ethylene and n-propylene groups and moieties.

Typically, as used herein, a C₆-C₁₀ aryl group or moiety is phenyl or naphthyl. Phenyl is preferred.

5 As used herein, a halogen is typically chlorine, fluorine, bromine or iodine and is preferably chlorine, bromine or fluorine.

As used herein, an alkoxy group is typically a said alkyl group attached to an oxygen atom. A haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3
10 said halogen atoms. Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX₃ and -OCX₃ wherein X is a said halogen atom, for example chlorine and fluorine. Particularly preferred haloalkyl groups are -CF₃ and -CCl₃. Particularly preferred haloalkoxy groups are -OCF₃ and -OCCl₃.

As used herein, a 5- to 10- membered heteroaryl group or moiety is a
15 monocyclic 5- to 10- membered aromatic ring, such as a 5- or 6- membered ring, containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from O, S and N. Examples include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, oxadiazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, imidazolyl and pyrazolyl groups. Pyrrolyl, oxazolyl, thiazolyl and
20 pyrazolyl groups are preferred.

As used herein, a 5- to 10- membered heterocyclyl group or moiety is a monocyclic non-aromatic, saturated or unsaturated cyclic group or moiety containing at least one, for example 1, 2 or 3, heteroatoms selected from N, O and S. Typically, it is a 3- to 6- membered ring. Preferably, it is a 5- or 6- membered ring.

25 Suitable heterocyclyl groups and moieties include pyrazolidinyl, piperidyl, piperazinyl, morpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolyl and pyrazolinyl groups and moieties. Piperazinyl and morpholinyl groups and moieties are preferred.

As used herein, a C₃-C₆ carbocyclic group or moiety is a monocyclic non-
30 aromatic saturated or unsaturated hydrocarbon ring having from 3 to 6 carbon atoms. Preferably it is a saturated hydrocarbon ring (i.e. a cycloalkyl group) having from 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. It is preferably cyclohexyl.

Typically, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents are unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl, -NR'[/]-CO₂-R''[/],
 5 -CO₂R''[/], -CO-R'''[/], -NR'-CO-R'''[/], -CONR'/R''[/], -SO₂NR'/R''[/], -SO₂R'''[/] and -O-(CH₂)_n-R'''[/]
 substituents, wherein n is from 0 to 4, each R'[/] is the same or different and represents hydrogen or C₁-C₄ alkyl, each R''[/] is the same or different and represents hydrogen, C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, each R'''[/] is the same or different and represents C₁-C₄ alkyl, a 5- or 6- membered
 10 heteroaryl group or a 5- or 6- membered heterocyclyl group, and each R'''[/] is the same or different and represents a 5- to 6- membered heteroaryl group or a 5- to 6- membered heterocyclyl group,

the heteroaryl and heterocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl and C₁-C₄ hydroxyalkyl
 15 groups.

More typically, these preferred substituents are selected from selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl, -NR'[/]-CO₂-R''[/], -CO₂R''[/], -CO-R'''[/],
 -NR'-CO-R'''[/], -CONR'/R''[/], -SO₂NR'/R''[/] and -SO₂R'''[/] substituents, wherein each R'[/] is the
 20 same or different and represents hydrogen or C₁-C₄ alkyl, each R''[/] is the same or different and represents hydrogen, C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, and each R'''[/] is the same or different and represents C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group,

the heteroaryl and heterocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl and C₁-C₄ hydroxyalkyl
 25 groups.

Typically, only one of the substituents on an aryl, heteroaryl, heterocyclyl or carbocyclyl moiety in the R₁ and R₂ substituents is a nitro, C₆-C₁₀ aryl, C₃-C₆
 30 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'[/]-CO₂-R''[/], -CO₂R''[/], -COR'''[/], -NR'-CO-R'''[/], -CONR'/R''[/], -SO₂NR'/R''[/], -SO₂R'''[/] or -O-(CH₂)_n-R'''[/] substituent. More typically, only one of the substituents on an aryl, heteroaryl,

heterocyclyl or carbocyclyl moiety in the R_1 and R_2 substituents is a cyano, nitro, C_6 - C_{10} aryl, C_3 - C_6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, $-NR'/CO_2R''$, $-CO_2R''$, $-COR'''$, $-NR'-CO-R'''$, $-CONR'/R''$, $-SO_2NR'/R''$, $-SO_2R'''$ or $-O-(CH_2)_n-R'''$ substituent.

5 Preferably, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R_1 and R_2 substituents are unsubstituted or substituted by 1 or 2 unsubstituted substituents selected from halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkoxy, cyano, 5- to 6- membered heteroaryl, for example oxazolyl and thiazolyl, 5- to 6- membered heterocyclyl, for example morpholinyl, $-CO_2R'$, $-CONR'/R''$, $-NR'-COR'''$,
10 $-SO_2NR'/R'''$ and $-O-(C_1-C_2 \text{ alkyl})-R_7$ substituents, wherein each R' and R'' are the same or different and represent hydrogen or C_1 - C_4 alkyl, each R''' is the same or different and represents a C_1 - C_4 alkyl group, each R''' is the same or different and represents hydrogen, C_1 - C_4 alkyl or 5- to 6- membered heteroaryl, for example thiazolyl, and each R_7 is the same or different and represents 5- to 6- membered heteroaryl, for example
15 pyridyl.

Typically, these preferred unsubstituted substituents are selected from halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkoxy, cyano, 5- to 6- membered heteroaryl, for example oxazolyl and thiazolyl, 5- to 6- membered heterocyclyl, for example morpholinyl, $-CO_2R'$, $-CONR'/R''$, $-NR'-COR'''$ and $-SO_2-$
20 NR'/R''' substituents, wherein each R' and R'' are the same or different and represent hydrogen or C_1 - C_4 alkyl, each R''' is the same or different and represents a C_1 - C_4 alkyl group and each R''' is the same or different and represents hydrogen, C_1 - C_4 alkyl or 5- to 6- membered heteroaryl, for example thiazolyl.

Typically, R_1 is a C_6 - C_{10} aryl or 5- to 10- membered heteroaryl group. More
25 typically, R_1 is a C_6 - C_{10} aryl group, for example a phenyl group. Further, R_1 is typically unsubstituted or substituted by 1, 2 or 3 substituents selected from C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halogen and C_1 - C_4 haloalkyl substituents. Preferably, R_1 is unsubstituted or substituted by 1 or 2 substituents selected from C_1 - C_4 alkyl, halogen and C_1 - C_4 haloalkyl substituents.

30 More preferably, R_1 is a phenyl group which is unsubstituted or substituted by 1 or 2 substituents selected from C_1 - C_4 alkyl, halogen and C_1 - C_4 haloalkyl substituents.

The R₂ substituent is typically monocyclic or bicyclic. Typically, R₂ is a C₃-C₆ carbocyclyl or 5- to 10- membered heterocyclyl group or is a C₆-C₁₀ aryl or 5- to 10- membered heteroaryl moiety which moiety is optionally fused to a C₃-C₆ carbocyclyl group or to a phenyl ring. Preferably, R₂ is a phenyl or 5- to 6- membered heteroaryl moiety which is optionally fused to a phenyl or C₃-C₆ cycloalkyl group. Most preferably, R₂ is a phenyl, indolyl, indazolyl or 5,6,7,8-tetrahydronaphthalenyl group.

Typically, when R₂ is a fused ring system it is unsubstituted. When R₂ is a monocyclic moiety, it is typically unsubstituted or carries the substituents set out above as appropriate for the cyclic moieties in the R₁ and R₂ substituents.

Typically, X is -NR', -NR'-CO-NR'', -NR'-L- or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C₁-C₄ alkyl group, and L represents a C₁-C₄ alkylene group. Preferably, R' and R'' are the same or different and each represent a C₁-C₂ alkyl group and L represents a C₁-C₂ alkylene group.

Preferred compounds of the invention are those in which:

- R₁ is a C₆-C₁₀ aryl or 5- to 10- membered heteroaryl group which is unsubstituted or substituted by 1, 2 or 3 substituents selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, halogen and C₁-C₄ haloalkyl substituents;
- R₂ is a C₃-C₆ carbocyclyl or 5- to 10- membered heterocyclyl group or is a C₆-C₁₀ aryl or 5- to 10- membered heteroaryl moiety which moiety is optionally fused to a C₃-C₆ carbocyclyl group or to a phenyl ring, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₂ substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl, -NR'-CO₂-R'', -CO₂R'', -CO-R''', -NR'-CO-R''', -CONR'R'', -SO₂NR'R'', -SO₂R''' and -O-(CH₂)_n-R'''' substituents, wherein n is from 0 to 4, each R' is the same or different and represents hydrogen or C₁-C₄ alkyl, each R'' is the same or different and represents hydrogen, C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, each R''' is the same or different and represents C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, and each R'''' is the same or different and represents a 5- to 6- membered heteroaryl group or a 5- to 6- membered heterocyclyl group, the heteroaryl and heterocyclyl moieties in said substituents being unsubstituted or

substituted by a further substituent selected from C₁-C₄ alkyl and C₁-C₄ hydroxyalkyl groups; and

- X is -NR', NR'-CO-NR'', -NR'-L- or -NR'-CO-L- wherein R' and R'' are the same or different and each represent hydrogen or a C₁-C₄ alkyl group and L represents a C₁-C₄ alkylene group.

Preferably, in the above preferred compounds of the invention, R₂ is a C₃-C₆ carbocyclyl or 5- to 10- membered heterocyclyl group or is a C₆-C₁₀ aryl or 5- to 10- membered heteroaryl moiety which moiety is optionally fused to a C₃-C₆ carbocyclyl group or to a phenyl ring, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₂ substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl, -NR'-CO₂-R'', -CO₂R'', -CO-R''', -NR'-CO-R''', -CONR'R'', -SO₂NR'R'' and -SO₂R''' substituents, wherein each R' is the same or different and represents hydrogen or C₁-C₄ alkyl, each R'' is the same or different and represents hydrogen, C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, and each R''' is the same or different and represents C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, the heteroaryl and heterocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl and C₁-C₄ hydroxyalkyl groups.

Most preferred compounds of the invention are those in which:

- R₁ is a phenyl group which is unsubstituted or substituted by 1 or 2 substituents selected from C₁-C₄ alkyl, halogen and C₁-C₄ haloalkyl substituents;
- R₂ is a phenyl, indolyl, indazolyl or 5,6,7,8-tetrahydronaphthalenyl group which is unsubstituted or substituted with 1 or 2 unsubstituted substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, for example oxazolyl and thiazolyl, 5- to 6- membered heterocyclyl, for example morpholiny, -CO₂R', -CONR'R'', -NR'-COR''', -SO₂-NR'R''' and -O-(C₁-C₂ alkyl)-R/ substituents, wherein each R' and R'' are the same or different and represent hydrogen or C₁-C₄ alkyl, each R''' is the same or different and represents a C₁-C₄ alkyl group, each R''' is the same or different and represents hydrogen, C₁-C₄ alkyl or 5- to 6- membered heteroaryl,

for example thiazolyl and each R₁ is the same or different and represents 5- to 6-membered heteroaryl, for example pyridyl; and

- X is -NR'¹-, -NR'¹-CO-NR''²-, -NR'¹-L- or -NR'¹-CO-L- wherein R'¹ and R''² are the same or different and each represent a C₁-C₂ alkyl group and L represents a C₁-C₂ alkylene group.

Typically, in these most preferred compounds of the invention, R₂ is a phenyl, indolyl, indazolyl or 5,6,7,8-tetrahydronaphthalenyl group which is unsubstituted or substituted with 1 or 2 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, for example oxazolyl and thiazolyl, 5- to 6- membered heterocyclyl, for example morpholinyl, -CO₂R'¹-, -CONR'¹/R''²-, -NR'¹-COR'''³ and -SO₂-NR'¹/R'''³ substituents, wherein each R'¹ and R''² are the same or different and represent hydrogen or C₁-C₄ alkyl, each R'''³ is the same or different and represents a C₁-C₄ alkyl group and each R'''³ is the same or different and represents hydrogen, C₁-C₄ alkyl or 5- to 6- membered heteroaryl, for example thiazolyl.

In a further embodiment of the invention, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₂ substituent do not carry a -CONR'¹/R''² substituent when X is -NR'¹- and R₁ is an unsubstituted phenyl group. Preferably, in this embodiment, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents do not carry a -CONR'¹/R''² substituent whatever moieties are present at the X and R₁ positions.

More preferably, in this embodiment, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents do not carry an -NR'¹-CO₂-R''²-, -CO₂R''²-, -COR'''³-, -NR'¹-CO-R'''³-, -CONR'¹/R''² or -SO₂-NR'¹/R'''³ substituent when X is -NR'¹-.

Most preferably, in this embodiment, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents do not carry an -NR'¹-CO₂-R''²-, -CO₂R''²-, -COR'''³-, -NR'¹-CO-R'''³-, -CONR'¹/R''² or -SO₂-NR'¹/R'''³ substituent whatever moiety is present at the X position.

In a further embodiment of the invention, X is other than -NR'¹-.

The medicaments of the present invention are for use in treating or preventing a flaviviridae infection, in particular a hepatitis C infection, in the human or animal body. Preferably, the medicaments are for use in humans.

Compounds of formula (I) containing one or more chiral centre may be used in enantiomerically or diastereoisomerically pure form, or in the form of a mixture of isomers. For the avoidance of doubt, the compounds of formula (I) can, if desired, be used in the form of solvates. Further, for the avoidance of doubt, the compounds of the invention may be used in any tautomeric form.

As used herein, a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or *p*-toluenesulphonic acid. Pharmaceutically acceptable bases include alkali metal (e.g. sodium or potassium) and alkali earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines and heterocyclic amines.

Particularly preferred compounds of formula (I) include:

1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-amine;
[2-(1H-Indol-3-yl)-ethyl]-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine;
(4-Butyl-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine;
(4-Butyl-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
(4-Ethoxy-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-ethoxy-phenyl)-amine;
4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzoic acid ethyl ester;
(5-Chloro-2-methoxy-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine;
(5-Chloro-2-methoxy-phenyl)-[1-(4-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
[1-(4-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-fluoro-phenyl)-amine;
4-{2-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-fluoro-phenyl)-amine;
4-{2-[1-(2-Bromo-phenyl)-3H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide;

[1-(2-Bromo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-butyl-phenyl)-amine;
4-[2-(1-o-Tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-ethyl]-benzenesulfonamide;
[2-(1H-Indol-3-yl)-ethyl]-(1-o-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine;
(4-Butyl-phenyl)-(1-o-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine;
5 4-{2-[1-(2,4-Dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-
benzenesulfonamide;
[1-(2,4-Dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-
amine;
[1-(2,4-Dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-ethoxy-phenyl)-amine;
10 4-{2-[1-(3-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-
benzenesulfonamide;
(4-Butyl-phenyl)-[1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
(5-Chloro-2-methoxy-phenyl)-[1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
amine;
15 4-{2-[1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-
benzenesulfonamide;
[1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-
amine;
[1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-ethoxy-phenyl)-amine;
20 (4-Butyl-phenyl)-[1-(2-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
(5-Chloro-2-methoxy-phenyl)-[1-(2-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
amine;
4-{2-[1-(2-Trifluoromethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-
benzenesulfonamide;
25 [2-(1H-Indol-3-yl)-ethyl]-[1-(2-trifluoromethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-
4-yl]-amine;
(3-Chloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
(3-Bromo-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-trifluoromethyl-
30 phenyl)-amine;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-trifluoromethyl-
phenyl)-amine;
3-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzonitrile;

- 4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzonitrile;
[1-(4-Bromo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-butyl-phenyl)-amine;
[1-(4-Bromo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(5-chloro-2-methoxy-phenyl)-
amine;
5 [1-(2,4-Difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-
amine;
(4-Butyl-phenyl)-[1-(2,4-difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
(5-Chloro-2-methoxy-phenyl)-[1-(2,4-difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
yl]-amine;
10 (3,5-Dichloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
amine;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-oxazol-5-yl-phenyl)-
amine;
(3-Chloro-4-fluoro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
15 yl]-amine;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(1H-indazol-5-yl)-amine;
1-(4-Chloro-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
urea;
(3,4-Dichloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
20 amine;
N-{4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-phenyl}-
acetamide;
4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzamide;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-oxazol-5-yl-phenyl)-
25 amine;
2-(2-Bromo-phenyl)-N-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
acetamide;
1-(4-Bromo-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
urea;
30 1-(2,3-Dichloro-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
yl]-urea;
1-(3,4-Dimethyl-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-
yl]-urea;


- 1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-(4-trifluoromethyl-phenyl)-urea;
4-{3-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-ureido}-benzenesulfonamide;
- 5 (3,4-Dichloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-methyl-amine;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-morpholin-4-yl-phenyl)-amine;
- 10 4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzenesulfonamide;
4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-N-thiazol-2-yl-benzenesulfonamide;
- 15 2-Chloro-4-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzonitrile;
[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine;
1-(4-Cyano-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-urea;
- 20 1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-(3-trifluoromethyl-phenyl)-urea;
1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-p-tolyl-urea;
(1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(5,6,7,8-tetrahydro-naphthalen-1-yl)-amine;
- 25 (2-Bromo-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine;
(1-Benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(2,4-dimethyl-phenyl)-amine;
[2-(4-Chloro-phenyl)-ethyl]-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
- 30 1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-[4-(pyridin-2-ylmethoxy)-phenyl]-urea;
1-[1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-[4-(pyridin-2-ylmethoxy)-phenyl]-urea;

5-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-[4-(pyridin-2-ylmethoxy)-phenyl]-urea;

1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-fluoro-4-morpholin-4-yl-phenyl)-amine.

5 and pharmaceutically acceptable salts thereof.

The present invention also provides a pharmaceutical composition comprising a pyrazolopyrimidine derivative of formula (I'), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluant or carrier,



wherein:

- 10 - R_1 is a phenyl group which is unsubstituted or substituted by 1 or 2 substituents selected from C_1 - C_4 alkyl, halogen and C_1 - C_4 haloalkyl substituents;
 - R_2 is a C_6 - C_{10} aryl, C_3 - C_6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C_6 - C_{10} aryl, C_3 - C_6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclic ring; and
 - 15 - X is $-NR'$ -, $-NR'$ -CO- NR'' -, $-NR'$ -L- or $-NR'$ -CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C_1 - C_6 alkyl group and L represents a C_1 - C_6 alkylene group,
- the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R_2 substituents
- 20 being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkoxy, cyano, nitro, C_6 - C_{10} aryl, C_3 - C_6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, $-NR'$ -CO- $2R''$, $-CO_2R''$, $-COR'''$, $-NR'$ -CO- R''' , $-CONR'R''$, $-SO_2NR'R''$, $-SO_2R'''$ and $-O-(CH_2)_n-R'''$ substituents, wherein n is from 0 to 4, each R' is the same or different
 - 25 and is hydrogen or C_1 - C_6 alkyl, each R'' is the same or different and is hydrogen, C_1 - C_6 alkyl, C_6 - C_{10} aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C_1 - C_6 alkyl, C_6 - C_{10} aryl, 5- to 10- membered

heterocyclyl or 5- to 10- membered heteroaryl, and each R^{'''} is the same or different and is C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl.

the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl, C₁-C₄ hydroxalkyl and C₁-C₄ haloalkyl groups.

Typically, in the compounds of formula (I'), the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₂ substituents are unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, nitro, C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'[']-CO₂-R'', -CO₂R'', -COR''', -NR'-CO-R''', -CONR'R'', -SO₂NR'R'' and -SO₂R''' substituents, wherein each R' is the same or different and is hydrogen or C₁-C₆ alkyl, each R'' is the same or different and is hydrogen, C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl and each R''' is the same or different and is C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl.


Preferred R₁, R₂ and X substituents in the formula (I') are the same as the preferred R₁, R₂ and X substituents set out above for the formula (I). Preferably, however, X in the formula (I') is -NR'-CO-NR''- or -NR'-CO-L- wherein R' and R'' are as defined above.

Also provided is a compound of formula (I'), as defined above, or a pharmaceutically acceptable salt thereof, provided that the compound of formula (I') is other than (1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(5,6,7,8-tetrahydro-naphthalen-1-yl)-amine, (2-Bromo-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine, 1-Benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(2,4-dimethyl-phenyl)-amine, [2-(4-Chloro-phenyl)-ethyl]-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine and 4-Anilino-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine.

The present invention further provides a pharmaceutical composition comprising a compound of formula (I) or a compound of formula (I'), or a pharmaceutically acceptable salt thereof, interferon and/or ribavirin and a pharmaceutically acceptable carrier or diluent.

The compounds of formula (I) and (I') can be prepared from intermediates of formula (IIa) or (IIb). Compounds of formulae (IIa) and (IIb) can be prepared via the

following reaction scheme. R_1 in the formulae (IIa) and (IIb) is as defined above. R' in the formula (IIa) represents hydrogen or a C_1 - C_6 alkyl group.




5

In the above reaction scheme, compounds of formula (IIa) which carry an amine (NH_2) substituent at the 4- position of the pyrazolopyrimidine ring can be prepared from an appropriate 5-amino-4-nitrile-pyrazole intermediate. Compounds of formula (IIa) in which the 4- substituent is an HNR' moiety, wherein R' is a C_1 - C_6 alkyl group, can be prepared either by reacting a corresponding primary amine with an appropriate electrophile (for example $\text{R}'\text{-Cl}$) or by reacting a compound of formula (IIb) with an appropriate secondary amine.

10


Compounds of formula (I) in which X is $-\text{NR}'$ - or $-\text{NR}'\text{-L-}$ can be obtained by reacting a compound of formula (IIb) with an amine $\text{HNR}'\text{R}$, wherein R corresponds to R_2 or $-\text{L-R}_2$, as follows.

15



Typically, the reaction is conducting by treating one equivalent of the compound of formula (IIb) in dry ethanol or other suitable inert solvent with three equivalents of the appropriate amine and heating to reflux overnight. The resulting solution can then be cooled to room temperature and diluted with water. The resulting precipitate can be isolated by filtration, dried in vacuo and if necessary purified further to give the desired product.


Compounds of formula (I) in which X is -NR'-CO-NH- can be obtained by reacting a compound of formula (IIa) with a compound R₂-NCO, wherein R₂ is as defined above.




Typically the reaction is conducted either by heating a solution of the appropriate aniline (1eq) and triethylamine (2eq) in anhydrous tetrahydrofuran at reflux for five minutes and adding to this triphosgene (1eq) in one portion, followed by heating the reaction mixture to generate the isocyanate, or by dissolving a commercially available isocyanate in anhydrous tetrahydrofuran and heating to 85°C. Separately, a solution of amino intermediate (1eq) and sodium hydride (1.1eq) in anhydrous tetrahydrofuran can be stirred at room temperature for 30 min. After 30 min, the solution of aminopyrazolopyrimidine can be added to the isocyanate solution and the mixture can be stirred under elevated temperature. The crude mixture can then be evaporated and the resulting solid partitioned between ethyl acetate and water. The

combined organic layers can be washed once with brine, and concentrated under reduced pressure, to give a crude product which can be purified by appropriate methods, for example chromatography and HPLC.

- 5 Compounds of formula (I) in which X is $-NR'-CO-NR''-$ and R'' is other than hydrogen can be prepared by reacting a compound of formula (IIa) with a compound of formula $R_2(R'')NCO-X$, wherein R_2 is as defined above, R'' is a C_1-C_6 alkyl group and X is a leaving group, for example chlorine, OPh or $OPh-NO_2$.




- 10 Alternatively, compounds of formula (I) in which X is $-NR'-CO-NR''-$ may be prepared by reaction of compounds (IIa) with an appropriate difunctional reagent $XCOX'$, wherein X and X' are leaving groups. Examples of appropriate difunctional reagents include those wherein $X=X'=Cl$ (phosgene), $X=Cl$ and $X'=OPh$ (phenylchloroformate) and $X=Cl$ and $X'=OPhNO_2$ (p-nitrochloroformate). The thus
- 15 obtained intermediate can subsequently be reacted with an appropriate nucleophile to give the desired compounds.



- 20 Alternatively, compounds of formula (I) in which X is $-NR'-CO-NR''-$ may be prepared by reaction of a compound of formula (I) in which X is $-NR'-CO-NH-$ with a strong, non-nucleophilic base, for example sodium hydride, and reaction of the resulting anion with an alkylating agent, for example an alkyl iodide. Clearly, if the compound desired has $R'=H$ then a temporary protecting group, for example a benzyl group, may be required at the R' position to prevent the formation of unwanted side products.

Compounds of formula (I) in which X is -NR'-CO-L- can be prepared by reacting a compound of formula (IIa) with R-CO-Cl, wherein R corresponds to -L-R₂, as follows.



Typically, the reaction is carried out by treating a suspension of amino intermediate in dry acetonitrile with acid chloride (1.2eq) and heating to reflux for 72h. The reaction mixtures can be partitioned between ethyl acetate and saturated bicarbonate solution and the organic phase separated and concentrated onto silica gel. The desired product can then be purified by standard techniques.

The starting materials used in the above reaction scheme are known compounds or may be prepared in accordance with known methods.

Certain compounds of formulae (IIa) and (IIb) are believed to be novel. These novel intermediates therefore also form part of the invention. The compounds in question are:

5-Amino-1-(2,4-dimethyl-phenyl)-1H-pyrazole-4-carbonitrile;

1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine;

1-(2-Bromo-phenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine;

4-Chloro-1-(2-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;

4-Chloro-1-(2,4-dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;

4-Chloro-1-(2-trifluoromethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;

4-Chloro-1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;

1-(4-Bromo-phenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine;

4-Chloro-1-(2,4-difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;

4-Chloro-1-p-tolyl-1H-pyrazolo[3,4-d]pyrimidine; and
1-Benzyl-4-chloro-1H-pyrazolo[3,4-d]pyrimidine.

As explained above, the compounds of the invention are active against flaviviridae, in particular against the hepatitis C virus. The present invention therefore provides a method for treating a patient suffering from or susceptible to a flaviviridae infection, in particular a hepatitis C infection, which method comprises administering to said patient an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Also provided is a method for alleviating or reducing the incidence of a hepatitis C infection in a patient, which method comprises administering to said patient an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

The compounds of the invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.

The compounds of the invention are typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar coating, or film coating processes.

Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.

Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

Compounds of the present invention may be used in conjunction with known anti-viral agents. Preferred known anti-viral agents in this regard are interferon and ribavirin, which are known for the treatment of hepatitis C (Clinical Microbiology Reviews, Jan. 2000, 67-82). The said medicament therefore typically further comprises interferon and/or ribavirin. Further, the present invention provides a pharmaceutical composition comprising:

- (a) a pyrazolopyrimidine derivative of the formula (I), as defined above, or a pharmaceutically acceptable salt thereof;
- (b) interferon and/or ribavirin; and
- (c) a pharmaceutically acceptable carrier or diluent.

Also provided is a product comprising:

- (a) a pyrazolopyrimidine derivative of the formula (I), as defined above, or a pharmaceutically acceptable salt thereof; and
 - (b) interferon and/or ribavirin,
- for separate, simultaneous or sequential use in the treatment of the human or animal body.

A therapeutically effective amount of a compound of the invention is administered to a patient. A typical dose is from about 0.01 to 100 mg per kg of body weight, according to the activity of the specific compound, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 0.05 to 16 mg per kg of body weight, more preferably, from 0.05 to 1.25 mg per kg of body weight.

The following Examples illustrate the invention. They do not however, limit the invention in any way. In this regard, it is important to understand that the particular

assay used in the Examples section is designed only to provide an indication of anti-hepatitis C activity. There are many assays available to determine such activity, and a negative result in any one particular assay is therefore not determinative.

EXAMPLES

All temperatures are in °C. Thin layer chromatography (TLC) was carried out on Si 60G coated plastic plates with uv254 indicator (Polygram). All NMR spectra were obtained at 250MHz in d⁶-DMSO unless stated otherwise.

LC-MS CONDITIONS

Samples were run on a MicroMass ZMD, using electrospray with simultaneous positive – negative ion detection.

Column : Synergi Hydro-RP, 30 x 4.6mm I.D, 4µm.

Gradient : 95:5 to 5:95 v/v H₂O/CH₃CN + 0.05% Formic Acid over 4.0 min, hold 3 min, return to 95:5 v/v H₂O/CH₃CN + 0.05% Formic Acid over 0.2 min and hold at 95:5 v/v H₂O/CH₃CN + 0.05% Formic Acid over 3 min.

Detection : PDA 250 – 340 nm.

Flow rate : 1.5 ml/min

Purification Method A

The crude material was dissolved in ethyl acetate and concentrated onto silica gel and loaded into an empty ISCO cartridge. Using an ISCO Combiflash Sq16x, purification was achieved by chromatography on silica gel with a hexane (solvent A) and ethyl acetate (solvent B) gradient ie

Time (min):	% solvent B
0	15
3	15
20	80
4	100
1	0

at a flow rate of 20ml/min with peak detection at 254nm.

Purification Method B

The crude material was dissolved in ethyl acetate and concentrated onto silica gel and loaded into an empty ISCO cartridge. Using an ISCO Combiflash Sq16x, purification

was achieved by chromatography on silica gel with a hexane (solvent A) and ethyl acetate (solvent B) gradient ie

Time (min):	% solvent B
0	40
3	40
20	100
4	100

at a flow rate of 20ml/min with peak detection at 254nm.

10

Purification Method C

Preparative HPLC was performed using a system comprising a Synergi Hydro-RP 50 x 21.2mm x 4µM column, Gilson 322 pump, Gilson UV/Vis-155 detection (at 254nm), and a Gilson 215 liquid handler under the control of Gilson Unipoint software in peak collection mode. Elution was performed at 25.6 ml/min with the mobile phase varied over time according to the table below, where solvent A is water + 0.05% formic acid and solvent B is acetonitrile + 0.05% formic acid.

15

Time = (min):	% solvent A	% solvent B
0	95	5
0.3	95	5
4	3	97
7	3	97
7.2	95	5
9	95	5

20

25

Intermediate 1: 4-chloro-1-(2,4-dimethylphenyl)-pyrazolo[3,4-d]pyrimidine

2,4-Dimethylphenylhydrazine hydrochloride (15.8g, 91.3mmol) was partitioned between 2M sodium hydroxide solution and dichloromethane. The organic layer was separated, dried and reduced under vacuum to give the free hydrazine (12.1g, 90.0mmol). The free hydrazine and ethoxymethylenemalononitrile (10.9g, 89.7mmol) were dissolved in anhydrous ethanol (40ml) and heated at reflux for two hours before

30

being chilled overnight. The product was filtered, washed with ice-cold ethanol and dried to give 5-amino-1-(2,4-dimethyl-phenyl)-1H-pyrazole-4-carbonitrile (13.8g, 65.1mmol, LC-MS rt 4.32 (MH)+ 213). 5-Amino-1-(2,4-dimethyl-phenyl)-1H-pyrazole-4-carbonitrile (10.0g, 47.2mmol) was added portionwise to stirred concentrated sulphuric acid (50ml) at 0°C. On completion of the addition, the mixture was allowed to warm to room temperature and stirred for a further one hour. The reaction solution was poured onto crushed ice and neutralised with concentrated ammonium hydroxide solution, while maintaining a temperature of 10-15°C, before being extracted with ethyl acetate. The organic layer was separated, dried over magnesium sulphate and reduced under vacuum to give 5-amino-1-(2,4-dimethylphenyl)pyrazole-4-carboxamide as a pale yellow solid (12.8g due to persisting organic solvent, LC-MS rt 3.79 (MH)+ 231). A suspension of 5-amino-1-(2,4-dimethylphenyl)-pyrazole-4-carboxamide (12.3g, 53.5mmol) in formamide was heated at 150°C for 48 hours. The cooled solution was diluted with water and allowed to stand. The product was filtered, washed with water and dried overnight in a vacuum oven to give 4-hydroxy-1-(2,4-dimethylphenyl)-pyrazolo[3,4-d]pyrimidine (10.8g, LC-MS rt 4.03 (MH)+ 241). A suspension of 4-hydroxy-1-(2,4-dimethylphenyl)pyrazolo[3,4-d]pyrimidine (1.5g, 6.3mmol) and phosphorus pentachloride (1.3g, 6.3mmol) in phosphorus oxychloride (15ml) was heated at reflux overnight. The solvent was removed under vacuum and the residue partitioned between ethyl acetate and water. The organic layer was separated, dried over magnesium sulphate and reduced under vacuum to give 4-chloro-1-(2,4-dimethylphenyl)-pyrazolo[3,4-d]pyrimidine as a yellow solid (1.4g, 5.4mmol)

LC-MS rt 5.32 (MH)+ 259/261

¹H NMR δ 8.87 (1H, s), 8.73 (1H, s), 7.22-7.36 (3H, m), 2.40 (3H, s), 2.03 (3H, s)

Intermediate 2: 1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine

2,4-Dimethylphenylhydrazine hydrochloride (15.8g, 91.3mmol) was partitioned between 2M sodium hydroxide solution and dichloromethane. The organics were separated, dried and reduced under vacuum to give the free hydrazine (12.1g, 90.0mmol). The free hydrazine and ethoxymethylenemalononitrile (10.9g, 89.7mmol) were dissolved in anhydrous ethanol (40ml) and heated at reflux for two hours before

being chilled overnight. The product was filtered, washed with ice-cold ethanol and dried to give 5-amino-1-(2,4-dimethyl-phenyl)-1H-pyrazole-4-carbonitrile (13.8g, 65.1mmol, LC-MS rt 4.32 (MH)+ 213). A suspension of 5-amino-1-(2,4-dimethyl-phenyl)-1H-pyrazole-4-carbonitrile (4.18g, 19.7mmol) in formamide (15ml) was heated at 150°C overnight. The reaction was cooled to room temperature and diluted with water. The product was filtered and washed with water and diethyl ether to give the title compound as a grey solid (2.86g, 12.0mmol)

LC-MS rt 3.55 (MH)+ 240

¹H NMR δ 8.31 (1H, s), 8.15 (1H, s), 7.81 (2H, br,d), 7.18-7.25 (3H, m), 2.37 (3H, s), 2.01 (3H, s)

Similarly prepared were the following intermediates:

Intermediate 3: 4-Chloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with free phenylhydrazine (4.55ml, 46.3mmol) gave the title compound as a yellow solid (0.81g, 3.5mmol)

LC-MS rt 5.62 (MH)+ 231

¹H NMR δ 8.90 (1H, s), 8.64 (1H, s), 8.07 (2H, d), 7.53 (2H, m), 7.35 (1H, t)

Intermediate 4: 4-Chloro-1-o-tolyl-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with o-Tolylhydrazine hydrochloride (5.44g, 34.3mmol) gave the title compound (~1.60g – solvent persisted in sample after drying).

LC-MS rt 5.39 (MH)+ 245

¹H NMR δ 8.80 (1H, s), 8.68 (1H, s), 7.36-7.44 (4H, m), 1.99 (3H, s)

Intermediate 5: 1-(2-Bromo-phenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with 2-bromophenylhydrazine hydrochloride (10.92g, 48.9mmol) gave the title compound as an orange solid (1.25g, 4.1mmol).

LC-MS rt 5.38 (MH)+ 309/311

¹H NMR δ 8.83 (1H, s), 8.73 (1H, s), 7.86 (1H, d,d), 7.51-7.64 (3H, m)

Intermediate 6: 4-Chloro-1-(4-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with 4-chlorophenylhydrazine hydrochloride (5.62g, 31.4mmol) gave the title compound as a pale yellow solid (2.85g, 10.7mmol)

5 LC-MS rt 6.05 (MH)⁺ 265

¹H NMR δ 9.06 (1H, s), 8.84 (1H, s), 8.26 (2H, d), 7.74 (2H, d)

Intermediate 7: 4-Chloro-1-(2-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine

10 Using the method of Intermediate 1 with 2-chlorophenylhydrazine hydrochloride (4.25g, 23.7mmol) gave the title compound as a yellow solid (1.15g, 4.3mmol).

LC-MS rt 4.97 (MH)⁺ 265

¹H NMR δ 8.96 (1H, s), 8.52 (1H, s), 7.66-7.86 (4H, m)

15 Intermediate 8: 4-Chloro-1-(2,4-dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with 2,4-dichlorophenylhydrazine hydrochloride (5.40g, 25.3mmol) gave the title compound as a dark orange solid (0.98g, 3.3mmol).

LC-MS rt 5.78 (MH)⁺ 299

20 ¹H NMR δ 8.94 (1H, s), 8.84 (1H, s), 8.38 (1H, s), 7.69 (2H, m)

Intermediate 9: 4-Chloro-1-(2-trifluoromethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with 2-trifluoromethylphenylhydrazine

25 hydrochloride (4.60g, 21.6mmol) gave the title compound as a crude orange solid (>100%) which was used without further purification.

LC-MS rt 5.41 (MH)⁺ 299

¹H NMR δ 8.90 (1H, s), 8.81 (1H, s), 8.60 (1H, d), 8.34 (1H, s), 7.87-7.98 (2H, m)

Intermediate 10: 4-Chloro-1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with 3-Chlorophenylhydrazine hydrochloride (10.92g, 61.0mmol) gave the title compound as a beige solid (1.02g, 3.8mmol)

5 LC-MS rt 6.15 (MH)⁺ 265

¹H NMR δ 9.05 (1H, s), 8.82 (1H, s), 8.32 (1H, t), 8.18 (1H, d,d), 7.67 (1H, t), 7.53 (1H, d,d)

Intermediate 11: 1-(4-Bromo-phenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine

10

Using the method of Intermediate 1 with 4-bromophenylhydrazine hydrochloride (5.28g, 23.6mmol) gave the title compound as a beige solid (0.73g, 2.4mmol).

LC-MS rt 6.22 (MH)⁺ 309/311

¹H NMR δ 9.07 (1H, s), 8.86 (1H, s), 8.21 (2H, d,d), 7.89 (2H, d,d)

15

Intermediate 12: 4-Chloro-1-(2,4-difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with 2,4-difluorophenylhydrazine hydrochloride (5.46g, 30.2mmol) gave the crude title compound as a beige solid.

20 LC-MS rt 5.33 (MH)⁺ 267

¹H NMR δ 9.00 (1H, s), 8.87 (1H, s), 7.72-7.93 (2H, m), 7.45 (1H, m)

Intermediate 13: 4-Chloro-1-p-tolyl-1H-pyrazolo[3,4-d]pyrimidine

25 Using the method of Intermediate 1 with p-tolylhydrazine hydrochloride (5.38g, 33.9mmol) gave the title compound as a brown solid (1.02g, 4.2mmol)

LC-MS rt 5.61 (MH)⁺ 245

¹H NMR δ 9.02 (1H, s), 8.79 (1H, s), 8.06 (2H, d), 7.47 (2H, d), 3.42 (3H, s)

30 Intermediate 14: 1-Benzyl-4-chloro-1H-pyrazolo[3,4-d]pyrimidine

Using the method of Intermediate 1 with benzylhydrazine dihydrochloride (2.70g, 13.8mmol) gave the title compound as a yellow solid (0.42g, 1.7mmol)

LC-MS rt 5.04 (MH)⁺ 245

¹H NMR δ 8.92 (1H, s), 8.54 (1H, s), 7.22-7.37 (5H, m), 5.71 (2H, s)

Example 1: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-amine

A suspension of Intermediate 1 (75mg, 1eq) in dry ethanol was treated with tryptamine (139mg, 3eq) and heated to reflux overnight. The resulting solution was cooled to room temperature and diluted with water. The resulting precipitate was isolated by filtration, dried in vacuo to give the desired product.

LCMS: rt 5.13 (MH)⁺ 383

¹H NMR δ 10.87 (1H, s), 8.56 (1H, t), 8.33 (1H, s), 8.28 (1H, s), 7.61 (1H, d), 7.36 (1H, d), 7.00-7.26 (m, 6H), 3.83 (2H, m), 3.07 (2H, t), 2.38 (3H, s), 2.02 (3H, s)

Prepared similarly were:

Example 2: [2-(1H-Indol-3-yl)-ethyl]-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine

Reaction of Intermediate 3 (100mg, 0.416mmol) with tryptamine (200mg) gave the title compound.

LCMS rt 5.27 (MH)⁺ 355

¹H NMR δ 10.86 (1H, s), 8.64 (1H, t), 8.42 (2H, d), 8.21 (2H, d), 7.58 (3H, m), 7.35 (2H, m), 7.22 (1H, d), 6.97-7.12 (2H, m), 3.84 (2H, m), 3.08 (2H, t)

Example 3: (4-Butyl-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine

Reaction of Intermediate 3 (50mg) with 4-butyraniline (3eq) gave the title compound.

LCMS: rt 6.71 (MH)⁺, 344

¹H NMR δ 10.20 (1H, s), 8.52 (2H, m), 8.22 (2H, d), 7.75 (2H, d), 7.58 (2H, t), 7.38 (1H, t), 7.25 (2H, d), 2.62 (2H, t), 1.23-1.50 (4H, m), 0.90 (3H, t)

Example 4: (4-Butyl-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 1 (75mg) with 4-butylaniline (137uL) gave the title compound after purification by Method A

LCMS: rt 6.64 (MH)⁺, 372

¹H NMR δ 10.14 (1H, s), 8.37 (2H, m), 7.73 (2H, d), 7.20-7.28 (5H, m), 2.60 (2H, t), 2.39 (3H, s), 2.03 (3H, s), 1.59 (2H, m), 1.34 (2H, m), 0.92 (3H, t)

Example 5: (4-Ethoxy-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine

Reaction of Intermediate 3 (100mg, 0.416mmol) with p-phenetidine (180uL) gave the title compound.

LCMS rt 5.7 (MH)⁺ 332

¹H NMR δ 10.12 (1H, s), 8.48 (1H, s), 8.21 (2H, d), 7.55-7.71 (4H, m), 7.37 (1H, t), 7.00 (1H, d), 4.05 (2H, q), 1.36 (3H, t)

Example 6: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-ethoxy-phenyl)-amine

Reaction of Intermediate 1 (75mg) with p-phenetidine (111uL) gave the title compound after purification by Method A

LCMS rt 5.61 (MH)⁺ 360

¹H NMR δ 10.07 (1H, s), 8.32 (2H, d), 7.68 (2H, d), 7.17-7.27 (3H, m), 6.99 (2H, d), 4.05 (2H, q), 2.39 (3H, s), 2.03 (3H, s), 1.35 (3H, t)

Example 7: 4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzoic acid ethyl ester

Reaction of Intermediate 1 (75mg) with ethyl 4-aminobenzoate (143mg) gave the title compound after purification by Method A

LCMS rt 6.07 (MH)⁺ 388

¹H NMR δ 10.53 (1H, s), 8.63 (1H, s), 8.51 (1H, s), 8.12 (2H, d) 8.02 (2H, d), 7.19-7.31 (3H, m), 4.33 (2H, q), 2.40 (3H, s), 2.04 (3H, s), 1.34 (3H, t)

Example 8: (5-Chloro-2-methoxy-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine

Reaction of Intermediate 3 (50mg) with 5-chloro-2-methoxyaniline (102mg) gave the title compound after purification by Method A.

LCMS rt 6.15 (MH)⁺ 352/354

¹H NMR δ 9.86 (1H, s), 8.49 (2H, s), 8.21 (2H, d), 7.91 (1H, d), 7.58 (2H, m), 7.17-7.41 (3H, m), 3.86 (3H, s)

Example 9: (5-Chloro-2-methoxy-phenyl)-[1-(4-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 6 (100mg) with 5-chloro-2-methoxyaniline (179mg) gave the title compound.

LCMS rt 6.85 (MH)⁺ 386/388

¹H NMR δ 9.91 (1H, s), 8.50 (2H, br s), 8.29 (2H, d), 7.89 (1H, d), 7.65 (2H, d), 7.32 (1H, d,d), 7.19 (1H, d), 3.86 (3H, s)

Example 10: [1-(4-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-fluoro-phenyl)-amine

Reaction of Intermediate 6 (100mg) with 3-fluoroaniline (109uL) gave the title compound.

LCMS rt 6.4 (MH)⁺ 340/342

¹H NMR δ 10.46 (1H, s), 8.65 (1H, s), 8.64 (1H, s), 8.30 (2H, d), 8.01 (1H, d,t), 7.59-7.68 (3H, m), 7.47 (1H, m), 6.99 (1H, t,d)

Example 11: 4-{2-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide

Reaction of Intermediate 1 (75mg) with 4-(2-Amino-ethyl)-benzenesulfonamide

5 (173mg) gave the title compound after purification by Method A

LCMS rt 4.55 (MH)⁺ 423

¹H NMR δ 8.55 (1H, t), 8.32 (1H, s), 8.27 (1H, s), 7.78 (2H, d), 7.49 (2H, d), 7.18-7.33 (3H, m), 3.80 (2H, q), 3.04 (2H, t), 2.38 (3H, s), 2.01 (3H, s)

10 Example 12: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-fluoro-phenyl)-amine

Reaction of Intermediate 1 (75mg) with 3-fluoroaniline (83.3uL) gave the title compound after purification by Method A

15 LCMS rt 5.86 (MH)⁺ 334

¹H NMR δ 10.38 (1H, s), 8.57 (1H, s), 8.48 (1H, s), 8.02 (1H, d,t), 7.61 (1H, d), 7.45 (1H, m), 7.22-7.30 (3H, m), 6.96 (1H, t,d), 2.39 (3H, s), 2.04 (3H, s)

20 Example 13: 4-{2-[1-(2-Bromo-phenyl)-3H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide

Reaction of Intermediate 5 (75mg) with 4-(2-amino-ethyl)-benzenesulfonamide (144mg) gave the title compound after purification by Method A.

LCMS rt 4.41 (MH)⁺ 473/475

25 ¹H NMR δ 8.60 (1H, t), 8.36 (1H, s), 8.28 (1H, s), 7.87 (1H, d), 7.78 (2H, d), 7.48-7.61 (5H, m), 3.80 (2H, m), 3.05 (2H, t)

Example 14: [1-(2-Bromo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-butyl-phenyl)-amine

30

Reaction of Intermediate 5 (75mg) with 4-butyl aniline (115uL) gave the title compound after purification by Method A

LCMS rt 6.26 (MH)⁺ 422/424

¹H NMR δ 10.20 (1H, s), 8.45 (1H, s), 8.38 (1H, s), 7.89 (1H, d), 7.72 (2H, d), 7.53-7.63 (3H, m), 7.25 (2H, d), 2.60 (2H, t), 1.58 (2H, m), 1.34 (2H, m), 0.93 (3H, t)

Example 15: 4-[2-(1-o-Tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-ethyl]-benzenesulfonamide

Reaction of Intermediate 4 (75mg) with 4-(2-amino-ethyl)-benzenesulfonamide (175mg) gave the title compound after purification by Method A.

LCMS rt 4.23 (MH)+ 409

¹H NMR δ 8.57 (1H, t), 8.34 (1H, s), 8.28 (1H, s), 7.77 (2H, d), 7.36-7.51 (6H, m), 7.32 (2H, s), 3.80 (2H, m), 3.05 (2H, t), 2.07 (3H, s)

Example 16: [2-(1H-Indol-3-yl)-ethyl]-(1-o-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine

Reaction of Intermediate 4 (75mg) with tryptamine (141mg) gave the title compound after purification by Method A.

LCMS rt 4.88 (MH)+ 369

¹H NMR δ 10.87, (1H, s), 8.58 (1H, t), 8.35 (1H, s), 8.29 (1H, s), 7.61 (1H, d), 7.35-7.45 (5H, m), 7.23 (1H, d), 7.00-7.09 (2H, m), 3.83 (2H, m), 3.08 (2H, t), 2.08 (3H, t)

Example 17: (4-Butyl-phenyl)-(1-o-tolyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine

Reaction of Intermediate 4 (75mg) with 4-butylaniline (140uL) gave the title compound after purification by Method A.

LCMS rt 6.18 (MH)+ 358

¹H NMR δ 10.15 (1H, s), 8.43 (1H, s), 8.38 (1H, s), 7.73 (2H, d), 7.40-7.47 (4H, m), 7.24 (2H, d), 2.56 (2H, t), 2.09 (3H, s), 1.59 (2H, m), 1.34 (2H, m), 0.93 (3H, t)

Example 18: 4-{2-[1-(2,4-Dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide

Reaction of Intermediate 8 (75mg) with 4-(2-amino-ethyl)-benzenesulfonamide (142mg) gave the title compound (6.5mg) after purification by Method A.

LCMS rt 4.83 (MH)+ 463

¹H NMR δ 8.63 (1H, t), 8.38 (1H, s), 8.30 (1H, s), 7.94 (1H, s), 7.78 (2H, d), 7.65-7.69 (2H, m), 7.48 (2H, d), 7.32 (2H, s), 3.80 (2H, m), 3.05 (2H, t)

Example 19: [1-(2,4-Dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-amine

10 Reaction of Intermediate 8 (75mg) with tryptamine (114mg) gave the title compound (7.1mg) after purification by Method A.

LCMS rt 5.45 (MH)+ 423

¹H NMR δ 10.87 (1H, s), 8.65 (1H, t), 8.38 (1H, s), 8.31 (1H, s), 7.94 (1H, s), 7.60-7.69 (3H, m), 7.36 (1H, d), 7.22 (1H, d), 6.97-7.12 (2H, m), 3.83 (2H, m), 3.07 (2H, t)

15

Example 20: [1-(2,4-Dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-ethoxy-phenyl)-amine

20 Reaction of Intermediate 8 (75mg) with p-phenetidine (92.4uL) gave the title compound (9.4mg) after purification by Method A.

¹H NMR δ 10.25 (1H, s), 8.60 (1H, br,s), 8.47 (1H, s), 8.07 (1H, s), 7.78 (4H, br, m), 7.11 (2H, d), 4.17 (2H, q), 1.47 (3H, t)

25 Example 21: 4-{2-[1-(3-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide

Reaction of Intermediate 10 (75mg) with 4-(2-amino-ethyl)-benzenesulfonamide (170mg) gave the title compound (63.9mg) after purification by Method A.

LCMS rt 5.22 (MH)+429/431

30 ¹H NMR δ 8.71 (1H, t), 8.50 (1H, s), 8.44 (2H, m), 8.26 (1H, d,d), 7.80 (2H, d), 7.43-7.66 (4H, m), 7.35 (2H, s), 3.84 (2H, m), 3.08 (2H, t)

Example 22: (4-Butyl-phenyl)-[1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

- 5 Reaction of Intermediate 10 (75mg) with 4-butyraniline (135uL) gave the title compound (50.6mg) after purification by Method A.

LCMS rt 7.52 (MH)⁺ 378/380

- ¹H NMR δ 10.09 (1H, s), 8.42 (1H, s), 8.38 (1H, br,s), 8.27 (1H, t), 8.11 (1H, d), 7.62 (2H, d), 7.51 (1H, t), 7.31 (1H, d), 7.16 (2H, d), 2.47 (2H, t), 1.45 (2H, m), 1.22 (2H, m), 0.80 (3H, t)
- 10

Example 23: (5-Chloro-2-methoxy-phenyl)-[1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

- 15 Reaction of Intermediate 10 (75mg) with 5-chloro-2-methoxy-aniline (25.3mg) gave the title compound (25.3mg) after purification by Method A.

LCMS rt 6.87 (MH)⁺ 386/388

- ¹H NMR δ 9.71 (1H, s), 8.31 (1H, s), 8.27 (1H, br,s), 8.20 (1H, t), 8.04 (1H, d), 7.68 (1H, d), 7.40 (1H, t), 7.24 (1H, d,d), 7.12 (1H, d,d), 7.00 (1H, d), 3.66 (3H, s)
- 20

Example 24: 4-{2-[1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide

- Reaction of Intermediate 7 (75mg) with 4-(2-amino-ethyl)-benzenesulfonamide (170mg) gave the title compound after purification by Method A.
- 25

LCMS rt 4.45 (MH)⁺ 429/431

- ¹H NMR δ 8.52 (1H, t), 8.27 (1H, s), 8.19 (1H, s), 7.68 (2H, d), 7.63 (1H, m), 7.4-7.51 (3H, m), 7.39 (2H, d), 7.23 (2H, s), 3.69 (2H, m), 2.95 (2H, t)

- 30 Example 25: [1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-amine

Reaction of Intermediate 7 (75mg) with tryptamine (137mg) gave the title compound after purification by Method A

LCMS rt 5.03 (MH)+ 389/391

¹H NMR δ 10.86 (1H, s), 8.61 (1H, t), 8.38 (1H, s), 8.30 (1H, s), 7.58-7.75 (5H, m),
5 7.36 (1H, d), 7.23 (1H, d), 7.00-7.09 (2H, m), 3.84 (2H, m), 3.08 (2H, t)

Example 26: [1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-ethoxy-phenyl)-amine

10 Reaction of Intermediate 7 (75mg) with p-phenetidine (110uL) gave the title compound after purification by Method A

LCMS rt 5.37 (MH)+ 366/368

¹H NMR δ 10.12 (1H, s), 8.47 (1H, br,s), 8.34 (1H, s), 7.56-7.77 (6H, m), 7.00 (2H, d),
15 4.06 (2H, q), 1.36 (3H, t)

Example 27: (4-Butyl-phenyl)-[1-(2-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 7 (75mg) with 4-butylaniline (135uL) gave the title compound
20 after purification by Method A

LCMS rt 6.32 (MH)+ 378/380

¹H NMR δ 9.96 (1H, s), 8.24 (1H, br,s), 8.16 (1H, s), 7.49-7.52 (3H, m), 7.34-7.43
(3H,m), 7.03 (2H, d), 2.36 (2H, t), 1.37 (2H, m), 1.12 (2H, m), 0.71 (3H, t)

25 Example 28: (5-Chloro-2-methoxy-phenyl)-[1-(2-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 7 (75mg) with 5-chloro-2-methoxy-aniline (135mg) gave the title compound after purification by Method A

30 LCMS rt 5.74 (MH)+ 386/388

¹H NMR δ 9.91 (1H, s), 8.51 (1H, br,s), 8.40 (1H, s), 7.96 (1H, d), 7.81 (1H, m), 7.65-
7.72 (3H, m), 7.38 (1H, d,d), 7.25 (1H, d), 3.92 (3H, s)

Example 29: 4-{2-[1-(2-Trifluoromethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-ethyl}-benzenesulfonamide

Reaction of Intermediate 9 (75mg) with 4-(2-amino-ethyl)-benzenesulfonamide

5 (170mg) gave the title compound (32.4mg) after purification by Method C

LCMS rt 4.58 (MH)⁺ 463

¹H NMR δ 8.70 (1H, t), 8.41 (1H, s), 8.33 (1H, s), 7.89-8.07 (3H, m), 7.83 (2H, d), 7.71 (1H, d), 7.54 (2H, d), 7.38 (2H, s), 3.86 (2H, m), 3.11 (2H, t)

10 Example 30: [2-(1H-Indol-3-yl)-ethyl]-[1-(2-trifluoromethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 9 (75mg) with tryptamine (140mg) gave the title compound (23.2mg) after purification by Method C

15 LCMS rt 5.14 (MH)⁺ 423

¹H NMR δ 10.91 (1H, s), 8.41 (1H, s), 8.33 (1H, s), 7.64-8.06 (5H, m), 7.41 (1H, d), 7.28 (1H, d), 7.04-7.13 (2H, m), 3.88 (2H, m), 3.13 (2H, t)

20 Example 31: (3-Chloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 1 (60mg) with 3-chloroaniline (105uL) gave the title compound after purification by Method A

LCMS rt 6.08 (MH)⁺ 350/352

25 ¹H NMR δ 10.33 (1H, s), 8.56 (1H, s), 8.48 (1H, s), 8.19 (1H, t), 7.79 (1H, d,d), 7.45 (1H, t), 7.28 (2H, d), 7.19 (2H, d), 2.40 (3H, s), 2.04 (3H, s)

Example 32: (3-Bromo-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 1 (60mg) with 3-bromoaniline (110uL) gave the title compound after purification by Method A

LCMS rt 6.16 (MH)⁺ 394/396

¹H NMR δ 10.32 (1H, s), 8.56 (1H, s), 8.48 (1H, s), 8.31 (1H, t), 7.85 (1H, d,t), 7.22-7.42 (5H, m), 2.39 (3H, s), 2.04 (3H, s)

Example 33: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-trifluoromethyl-phenyl)-amine

Reaction of Intermediate 1 (60mg) with 3-trifluoromethylaniline (125uL) gave the title compound after purification by Method A.

LCMS rt 6.17 (MH)⁺ 384

¹H NMR δ 10.42 (1H, s), 8.52 (1H, s), 8.42 (1H, s), 8.32 (1H, s), 8.14 (1H, d), 7.60 (1H, t), 7.43 (1H, d), 7.15-7.24 (3H, m), 2.33 (3H, s), 1.97 (3H, s)

Example 34: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine

Reaction of Intermediate 1 (60mg) with 4-trifluoromethylaniline (125uL) gave the title compound after purification by Method A

LCMS rt 6.25 (MH)⁺ 384

¹H NMR δ 10.48 (1H, s), 8.58 (1H, s), 8.46 (1H, s), 8.13 (2H, d), 7.74 (1H, d), 7.18-7.27 (3H, m), 2.35 (3H, s), 2.00 (3H, s)

Example 35: 3-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzonitrile

Reaction of Intermediate 1 (60mg) with 3-aminobenzonitrile (120mg) gave the title compound after purification by Method A

LCMS rt 5.68 (MH)⁺ 341

^1H NMR δ 10.51 (1H, s), 8.58 (1H, s), 8.52 (1H, s), 8.10 (1H, d,d), 7.62 (2H, m), 7.19-7.31 (3H, m), 2.40 (3H, s), 2.04 (3H, s)

Example 36: 4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzonitrile

Reaction of Intermediate 1 (60mg) with 4-aminobenzonitrile (120mg) gave the title compound after purification by Method A

LCMS rt 5.73 (MH)+ 341

^1H NMR δ 10.67 (1H, s), 8.69 (1H, s), 8.59 (1H, s), 8.24 (2H, d), 7.94 (2H, d), 7.28-7.37 (3H, m), 2.45 (3H, s), 2.09 (3H, s)

Example 37: [1-(4-Bromo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-butyl-phenyl)-amine

Reaction of Intermediate 11 (75mg) with 4-butylaniline (115uL) gave the title compound after purification by Method A

LCMS rt 7.62 (MH)+ 422/424

^1H NMR δ 10.32 (1H, s), 8.63 (2H, br,s), 8.34 (2H, d,d), 7.81-7.89 (4H, m), 7.33 (2H, d), 2.69 (2H, t), 1.67 (2H, m), 1.41 (2H, m), 1.01 (3H, t)

Example 38: [1-(4-Bromo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(5-chloro-2-methoxy-phenyl)-amine

Reaction of Intermediate 11 (75mg) with 5-chloro-2-methoxyaniline (100mg) gave the title compound after purification by Method A

LCMS rt 7.07 (MH)+ 430/432

^1H NMR δ 9.90 (1H, s), 8.50 (2H, br,s), 8.23 (2H, d,d), 7.89 (1H, d), 7.77 (2H, d,d), 7.31 (1H, d,d), 7.18 (1H, d)

Example 39: [1-(2,4-Difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-[2-(1H-indol-3-yl)-ethyl]-amine

Reaction of Intermediate 12 (100mg) with tryptamine (140mg) gave the title compound after purification by Method A

LCMS rt 5.11 (MH)+ 391

¹H NMR δ 8.57 (1H, t), 8.34 (1H, s), 8.27 (1H, s), 7.50-7.74 (5H, m), 7.43 (2H, d), 7.27 (2H, s), 3.75 (2H, m), 2.99 (2H, t)

Example 40: (4-Butyl-phenyl)-[1-(2,4-difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 12 (100mg) with 4-butylaniline (130uL) gave the title compound after purification by Method A

LCMS rt 6.4 (MH)+ 380

¹H NMR δ 10.03 (1H, s), 8.31 (1H, br,s), 8.22 (1H, s), 7.39-7.61 (4H, m), 7.16 (1H, t), 7.07 (2H, d), 2.40 (2H, t), 1.41 (2H, m), 1.17 (2H, m), 0.76 (3H, t)

Example 41: (5-Chloro-2-methoxy-phenyl)-[1-(2,4-difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 12 (100mg) with 5-chloro-2-methoxyaniline (135mg) gave the title compound after purification by Method A

LCMS rt 5.75 (MH)+ 388/390

¹H NMR δ 9.89 (1H, s), 8.48 (1H, br,s), 8.38 (1H, s), 7.88 (1H, d), 7.57-7.83 (2H, m), 7.34 (2H, m), 7.19 (1H, d), 3.86 (3H, s)

Example 42: (3,5-Dichloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

30

Reaction of Intermediate 1 (75mg) with 3,5-dichloroaniline (95mg) gave the title compound after purification by Method A

LCMS rt 6.22 (M-H)- 382/384

^1H NMR δ 10.46 (1H, s), 8.57 (1H, s), 8.55 (1H, s), 7.19-7.35 (4H, m), 2.40 (3H, s), 2.03 (3H, s)

Example 43: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-oxazol-5-yl-phenyl)-amine

Reaction of Intermediate 1 (75mg) with 4-oxazol-5-yl-phenylamine (95mg) gave the title compound after purification by Method B

LCMS rt 5.22 (MH)⁺ 383

^1H NMR δ 10.37 (1H, s), 8.57 (1H, s), 8.45 (2H, d), 8.05 (2H, d), 7.79 (2H, d), 7.65 (1H, s), 7.22-7.30 (3H, m), 2.40 (3H, s), 2.04 (3H, s)

Example 44: (3-Chloro-4-fluoro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 1 (75mg) with 3-chloro-4-fluoroaniline (84mg) gave the title compound after purification by Method A

LCMS rt 5.68 (MH)⁺ 368

^1H NMR δ 10.55 (1H, s), 8.72 (1H, s), 8.65 (1H, s), 8.47 (1H, d,d), 7.95 (1H, m), 7.67 (1H, t), 7.40-7.49 (3H, m), 2.58 (3H, s), 2.22 (3H, s)

Example 45: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(1H-indazol-5-yl)-amine

Reaction of Intermediate 1 (75mg) with 5-aminoindazole (77mg) gave the title compound after purification by Method B

LCMS rt 4.39 (MH)⁺ 356

^1H NMR δ 10.28 (1H, s), 8.43 (1H, s), 8.34 (1H, br,s), 8.18 (1H, s), 7.68 (2H, t), 7.23-7.34 (3H, m), 2.45 (3H, s), 2.06 (3H, s)

Example 47: (3,4-Dichloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

Reaction of Intermediate 1 (75mg) with 3,4-dichloroaniline (95mg) gave the title compound after purification by Method A

LCMS rt 6.05 (MH)⁺ 384/386

¹H NMR δ 10.68 (1H, s), 8.81 (1H, s), 8.74 (1H, s), 8.63 (1H, d), 8.09 (1H, d,d), 7.91 (1H, d), 7.46-7.54 (3H, m), 2.63 (3H, s), 2.27 (3H, s)

Example 48: N-{4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-phenyl}-acetamide

Reaction of Intermediate 1 (75mg) with N-(4-amino-phenyl)-acetamide (87mg) gave the title compound after purification by Method A

LCMS rt 4.39 (M-H)⁻ 371

¹H NMR δ 10.15 (1H, s), 9.99 (1H, s), 8.40 (1H, br, s), 8.36 (1H, s), 7.74 (2H, d), 7.62 (2H, d), 7.17-7.28 (3H, m), 2.39 (3H, s), 2.06 (3H, s), 2.03 (3H, s)

Example 49: 4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzamide

Reaction of Intermediate 1 (75mg) with 4-amino-benzamide (80mg) gave the title compound after purification by Method A

LCMS rt 4.35 (M-H)⁻ 357

¹H NMR δ 10.39 (1H, s), 8.59 (1H, s), 8.48 (1H, s), 8.00 (2H, d), 7.93 (2H, d), 7.18-7.30 (3H, m), 2.39 (3H, s), 2.03 (3H, s)

Example 50: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-oxazol-5-yl-phenyl)-amine

Reaction of Intermediate 1 (75mg) with 3-oxazol-5-yl-phenylamine (95mg) gave the title compound after purification by Method B

LCMS rt 5.16 (M-H)⁻ 381

¹H NMR δ 10.35 (1H, s), 8.55 (1H, s), 8.51 (1H, s), 8.46 (1H, s), 8.26 (1H, s), 7.95 (1H, m), 7.73 (1H, s), 7.54 (2H, d), 7.18-7.30 (3H, m), 2.39 (3H, s), 2.04 (3H, s)

Example 57: (3,4-Dichloro-phenyl)-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-methyl-amine

Reaction of Intermediate 1 (75mg) with (3,4-dichloro-phenyl)-methyl-amine (110uL) gave the title compound after purification by Method A

LCMS rt 5.98 (MH)+398/400

¹H NMR δ 8.30 (1H, s), 7.89 (1H, d), 7.79 (1H, d), 7.51 (1H, d,d), 7.10-7.16 (3H, m), 6.78 (1H, s), 3.55 (3H, s), 2.29 (3H, s), 1.89 (3H, s)

Example 58: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine

Reaction of Intermediate 1 (75mg) with 4-trifluoromethoxyaniline (105uL) gave the title compound after purification by Method A

LCMS rt 5.82 (MH)+ 400

¹H NMR δ 10.35 (1H, s), 8.55 (1H, s), 8.43 (1H, s), 8.01 (2H d,d), 7.43 (2H, d), 7.21-7.30 (3H, m), 2.39 (3H, s), 2.04 (3H, s)

Example 59: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(4-morpholin-4-yl-phenyl)-amine

Reaction of Intermediate 1 (75mg) with 4-morpholin-4-yl-phenylamine (105uL) gave the title compound after purification by Method A

LCMS rt 4.78 (MH)+ 401

¹H NMR δ 10.09 (1H, s), 8.40 (2H, br,s), 7.73 (2H, d), 7.29-7.36 (3H, m), 7.11 (2H, d), 3.87 (4H, t), 3.22 (4H, t), 2.48 (3H, s), 2.12 (3H, s)

Example 60: 4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzenesulfonamide

Reaction of Intermediate 1 (75mg) with 4-amino-benzenesulfonamide (100mg) gave the title compound after purification by Method A

LCMS rt 4.57 (MH)⁺ 395

¹H NMR δ 10.63 (1H, s), 8.76 (1H, s), 8.65 (1H, s), 8.26 (2H, d), 8.02 (2H, d), 7.37-7.46 (3H, m), 2.55 (3H, s), 2.20 (3H, s)

Example 61: 4-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-N-thiazol-2-yl-benzenesulfonamide

Reaction of Intermediate 1 (75mg) with 4-amino-N-thiazol-2-yl-benzenesulfonamide (150mg) gave the title compound after purification by Method C

LCMS rt 4.63 (MH)⁺ 478

¹H NMR δ 10.66 (1H, s), 8.70 (1H, s), 8.48 (1H, s), 8.11 (2H, d), 7.85 (2H, d), 7.16-7.30 (5H, m), 6.83 (1H, d), 3.9 (3H, s), 2.03 (3H, s)

Example 62: 2-Chloro-4-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-benzonitrile

Reaction of Intermediate 1 (75mg) with 2-chloro-4-aminobenzonitrile (90mg) gave the title compound after purification by Method A

LCMS rt 5.76 (MH)⁺ 375

¹H NMR δ 10.73 (1H, s), 8.64 (2H, d), 8.55 (1H, d), 8.00-8.09 (2H, m), 7.20-7.34 (3H, m), 2.43 (3H, s), 2.06 (3H, s)

Example 63: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(1H-indol-5-yl)-amine

Reaction of Intermediate 1 (75mg) with 5-aminoindole (75mg) gave the title compound after purification by Method A

LCMS rt 4.62 (MH)⁺ 355

^1H NMR δ 10.91 (1H, s), 9.79 (1H, s), 8.06 (1H, s), 7.68 (1H, br,s), 6.91-7.24 (5H, m), 6.23 (2H, m), 2.14 (3H, s), 1.78 (3H, s)

Example 46: 1-(4-Chloro-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-urea

A solution of Intermediate 2 (50mg, 0.208mmol, 1eq) and sodium hydride (1.1eq) in anhydrous tetrahydrofuran (2.5ml) was stirred at room temperature for 30min. This solution was added to a solution of 4-chlorophenyl isocyanate (1eq) in anhydrous THF (2.5ml) pre-heated to 85°C and the mixture was stirred for another 30min at 85°C. The crude mixture was evaporated and the resulting solid was partitioned between ethyl acetate and water. The combined organic layers were washed once with brine, and concentrated under reduced pressure, to give a crude white powder which was purified by Method C to give the title compound (12.7mg, 0.03mmol)

LCMS rt 5.78 (MH)⁺ 393

^1H -NMR (CDCl_3): 11.76 (bs, NH), 10.92 (bs, NH), 8.70 (s, 1H), 8.59 (s, 1H), 7.63 (d, J=8.75Hz; 2H), 7.36 (d, J=8.75Hz; 2H), 7.24 (d, J=8Hz; 2H), 7.17 (d, J=8Hz; 1H), 2.32 (s, 3H), 1.94 (s, 3H)

Similarly prepared were:

Example 52: 1-(4-Bromo-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-urea

Reaction of Intermediate 2 (50mg, 0.209mmol) with 4-bromophenyl isocyanate (1.1eq) gave the title compound.

LCMS rt 5.90 (MH)⁺ 437

^1H -NMR (CDCl_3): 11.76 (bs, NH), 10.92 (bs, NH), 8.71 (s, 1H), 8.59 (s, 1H), 7.58 (d, J=8.75Hz; 2H), 7.49 (d, J=8.75Hz; 2H), 7.24 (d, J=8Hz; 2H), 7.15 (d, J=8Hz; 1H), 2.32 (s, 3H), 1.93 (s, 3H)

Example 53: 1-(2,3-Dichloro-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-urea

Reaction of Intermediate 2 (50mg) with 2,3-dichlorophenyl isocyanate (1.1eq) gave the title compound.

LCMS rt 6.14 (MH)⁺ 427

¹H NMR δ 11.97 (bs, NH), 11.08 (bs, NH), 8.79 (s, 1H), 8.68 (s, 1H), 7.56 (d, J=2.5Hz; 2H), 7.19-7.32 (m; 4H), 2.38 (s, 3H), 2.01 (s, 3H)

Example 54: 1-(3,4-Dimethyl-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-urea

Reaction of Intermediate 2 (50mg) with 3,4-dimethylphenyl isocyanate (1.1eq) gave the title compound

LCMS rt 5.88 (MH)⁺ 387

¹H NMR δ 11.52 (bs, NH), 10.88 (bs, NH), 8.80 (s, 1H), 8.67 (s, 1H), 7.11-7.41 (m; 6H), 2.40 (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.02 (s, 3H)

Example 55: 1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-(4-trifluoromethyl-phenyl)-urea

Reaction of Intermediate 2 (50mg) with 4-trifluoromethylphenyl isocyanate (1.1eq) gave the title compound

LCMS rt 5.86 (MH)⁺ 427

¹H NMR δ 11.74 (bs, NH), 10.86 (bs, NH), 8.60 (s, 1H), 8.49 (s, 1H), 7.70 (d, J=7.5Hz; 2H), 7.53 (d, J=7.5Hz; 2H), 7.09 (d, J=7.5Hz; 2H), 7.03 (d, J=7.5Hz; 1H), 2.20 (s, 3H), 1.81 (s, 3H)

Example 51: 2-(2-Bromo-phenyl)-N-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-acetamide

A suspension of Intermediate 2 (50mg) in dry acetonitrile was treated with (2-bromo-phenyl)-acetyl chloride (38uL, 1.2eq) and heated to reflux for 72h. The reaction

mixture was partitioned between ethyl acetate and a saturated sodium bicarbonate solution and the organic phase separated and concentrated. Purification using Method A gave the title compound

LCMS rt 5.43 (MH)⁺ 436/438

5 ¹H NMR δ 11.71 (1H, s), 8.67 (1H, s), 8.61 (1H, s), 7.66 (1H, d,d) 7.51 (1H, d,d), 7.41 (1H, d,t) 7.19-7.31 (4H, m), 4.16 (2H, s), 2.39 (3H, s), 2.00 (3H, s)

Example 56: 4-{3-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-ureido}-benzenesulfonamide

10

4-Amino-benzenesulfonamide (36mg, 0.208mmol, 1eq) and triethylamine (2eq) in anhydrous THF (2.5ml) was heated at reflux for five minutes followed by the addition of triphosgene (1eq) in one portion. The reaction mixture was heated at 85° for 30 minutes to generate the isocyanate. Separately, a solution of Intermediate 2 (50mg,
15 0.208mmol, 1eq) and sodium hydride (1.1eq) in anhydrous tetrahydrofuran (2.5ml) was stirred at room temperature for 30min then added to the solution of isocyanate at 85°C and the mixture was stirred for another 30min at 85°C. The crude mixture was evaporated and the resulting solid was partitioned between ethyl acetate and water. The combined organic layers were washed once with brine, and concentrated under reduced
20 pressure, to give a crude white powder which was purified by Method C to give the title compound.

LCMS rt 4.67 (MH)⁺ 438

¹H-NMR (CDCl₃): 11.91 (bs, NH), 11.03 (bs, NH), 8.80 (s, 1H), 8.69 (s, 1H), 7.84 (s, 4H), 7.23-7.29 (m, 3H), 2.40 (s, 3H), 2.02 (s, 3H)

25

Prepared similarly were:

Example 64: 1-(4-Cyano-phenyl)-3-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-urea

30

Reaction of Intermediate 2 (50mg, 0.208mmol) with 4-amino-benzonitrile (1eq) gave the title compound

LCMS rt 5.34 (MH)⁺ 384

¹H NMR (CDCl₃): 11.99 (bs, NH), 11.22 (bs, NH), 8.78 (s, 1H), 8.68 (s, 1H), 7.86 (s, 5H), 7.31 (d, J=7.5Hz; 1H), 7.22 (d, J=7.5Hz; 1H), 2.40 (s, 3H), 2.02 (s, 3H)

5 Example 65: 1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-(3-trifluoromethyl-phenyl)-urea

Reaction of Intermediate 2 (50mg, 0.208mmol) with 3-trifluoromethyl-phenylamine (1eq), as above, gave the title compound

LCMS rt 5.87 (MH)⁺ 427

10 ¹H NMR δ (CDCl₃): 12.13 (bs, NH), 10.68 (bs, NH), 8.63 (s, 2H), 7.85 (d, J=12.5Hz; 2H), 7.47 (t, J=7.5Hz; 1H), 7.37 (d, J=7.5Hz; 1H), 7.10-7.25 (m, 3H), 2.35 (s, 3H), 2.04 (s, 3H)

15 Example 66: 1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-p-tolyl-urea

Reaction of Intermediate 2 (50mg, 0.208mmol) with p-tolylamine (1eq), as above, gave the title compound

LCMS rt 5.70 (MH)⁺ 373

20 ¹H-NMR (CDCl₃): 12.13 (bs, NH), 10.68 (bs, NH), 8.69 (s, 1H), 8.59 (s, 1H), 7.49 (d, J=7.5Hz; 2H), 7.13-7.24 (m, 5H), 2.35 (s, 3H), 2.29 (s, 3H), 2.03 (s, 3H)

Example 67: (1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(5,6,7,8-tetrahydro-naphthalen-1-yl)-amine

25

Purchased from IFLabs

Example 68: (2-Bromo-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine

30 Purchased from Interbioscreen

Example 69: (1-Benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(2,4-dimethyl-phenyl)-amine

5 Purchased from Interbioscreen

Example 70: [2-(4-Chloro-phenyl)-ethyl]-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine

10 Purchased from IFLabs

Example 71: [1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-(3-fluoro-4-morpholin-4-yl-phenyl)-amine

15 3,4-Difluoronitrobenzene (2.52g) was added to a solution of morpholine (6.0ml) in THF (10ml) at 0°. The reaction mixture was allowed to warm to rt and stirred for a further hour. The mixture was diluted with 1M citric acid solution and toluene and the organic phase separated, washed with water, dried and concentrated *in vacuo* to give an orange solid (2.43g). This solid was dissolved in 1:1 toluene: ethanol (50ml) and
20 subjected to hydrogenation over 10%/C (200mg) at RTP. The catalyst was removed by filtration and the solvent removed to give the desired amine as a beige solid (2.05g)
A portion of this amine (75mg) and Intermediate 1 (100mg) were combined by the method of Example 1 to give the title compound by purification method 1.

LCMS (MH)+ 419

25 ¹H NMR δ (DMSO): 10.25 (bs, NH), 8.54 (bs, NH), 8.43 (s, 1H), , 7.94 (d, J=15.2Hz; 1H), 7.5 (d, J= 7.6, 1H), 7.2-7.3 (m, 4H), 3.8 (4H, m), 3.05 (4H, m), 2.41 (3H, s), 2.05 (3H, s)

Example 72: 5-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-2-morpholin-4-yl-benzonitrile
30

2-Fluoro-5-nitrobenzene (1.0g) in MeCN (30ml) was treated with morpholine (1.0ml) and triethylamine (1.65ml) before being heated to reflux overnight. The mixture was

concentrated and partitioned between 1M citric acid solution and DCM and the organic phase separated, washed with water, dried and concentrated *in vacuo* to give an orange solid (1.52g). This solid was dissolved in 1:1 toluene: ethanol (50ml) and subjected to hydrogenation over 10%/C (150mg) at RTP. The catalyst was removed by filtration and the solvent removed to give the desired amine as a tan solid (1.38g)

A portion of this amine (80mg) and Intermediate 1 (100mg) were combined by the method of Example 1 to give the title compound by purification method 1.

LCMS (MH)⁺ 426

¹H NMR δ₂(DMSO): 10.33 (bs, NH), 8.49 (bs, NH), 8.42 (s, 1H), 8.34 (1H, d), 7.96 (dd, J=8.85Hz; 1H), 7.15-7.3 (m, 4H), 3.77 (4H, m), 3.13 (4H, m), 2.37 (3H, s), 2.02 (3H, s)

Example 73: 1-[1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-[4-(pyridin-2-ylmethoxy)-phenyl]-urea

A solution of di-*tert*-butyldicarbonate (15g) in THF (50ml) was added to a solution of 4-aminophenol (7.48g) in THF (100ml). Stirred overnight then concentrated and triturated with Et₂O / DCM whereupon the product spontaneously crystallised. Petrol was added and the solution concentrated slightly *in vacuo* and the resulting cold suspension filtered to give a first crop of solid. The filtrate was diluted further with petrol and concentrated to give a second crop that was combined with the first to give 4-*tert*-butoxycarbonylaminophenol (12.46g). A portion of this material (2.1g) and powdered K₂CO₃ (6.25g) in MeCN (100ml) was treated with 2-bromomethylpyridine (1eq, 2.54g) and heated to 80° for 3h. The cooled RM was concentrated and after aqueous workup the residue was purified by column chromatography on silica gel with EtOAc / hexane (2:3 to 3:2) as eluant. This gave the desired alkylated product as a pale yellow solid (2.2g) which was dissolved in DCM (10ml), cooled to 0° and treated with TFA (5ml) and stirred for 2h. The mixture was poured into 2N NaOH and extracted in DCM (3x25ml). Concentration of the combined organic phase gave the amine as a brown oil (700mg). This amine (90mg) was used to generate the corresponding isocyanate *in situ* using triphosgene and triethylamine. This isocyanate was treated with Intermediate 2 by the method of Example 46 to give the desired title compound (12mg)

¹H NMR δ 11.4 (1H, s), 10.84 (1H, s), 8.77 (1H, s), 8.63 (1H, s), 8.58 (2H, d), 7.84 (1H, t), 7.53 (2H, m), 7.4-7.0 (5H, m), 5.18 (2H, s), 2.39 (3H, s), 2.0 (3H, s)

Example 74: 1-[1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-3-[4-(pyridin-2-ylmethoxy)-phenyl]-urea

In a similar way to Example 73, the amine monomer was used to generate the corresponding isocyanate *in situ* using triphosgene and triethylamine. This isocyanate was treated with 1-(2-Chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine (prepared as per Intermediate 2) by the method of Example 46 to give the desired title compound (10mg)

¹H NMR δ 11.28 (1H, s), 10.86 (1H, s), 8.82 (1H, s), 8.65 (1H, s), 8.57 (2H, m), 8.0-7.5 (8H, m), 7.32 (2H, d), 7.05 (2H, d), 6.94 (1H, d), 5.18 (2H, s)

Activity Example

Cells used:

HCV replicon cells Huh 9B (ReBlikon), containing the firefly luciferase – ubiquitin – neomycin phosphotransferase fusion protein and EMCV-IRES driven HCV polyprotein with cell culture adaptive mutations.

Cell culture conditions:

Cells were cultured at 37°C in a 5% CO₂ environment and split twice a week on seeding at 2 x 10⁶ cells/flask on day 1 and 1 x 10⁶ 3 days later. Some 0.25mg/ml G418 was added to the culture medium (125ul per 25ml) but **not** the assay medium.

The culture medium consisted of DMEM with 4500g/l glucose and glutamax (Gibco 61965-026) supplemented with 1 x non-essential amino acids, penicillin (100 IU/ml) / streptomycin (100 µg/ml), FCS (10%, 50ml) and 1 mg/ml G418 (Invitrogen cat no 10131-027) & 10 % foetal calf serum.

Assay procedure:

A flask of cells was trypsinised and a cell count carried out. Cells were diluted to 100,000 cells/ml and 100 µl of this used to seed one opaque white 96-well plate (for the

replicon assay) and one flat-bottomed clear plate (for the tox assay) for every seven compounds to be tested for IC₅₀. Wells G12 and H12 were left empty in the clear plate as the blank. Plates were then incubated at 37°C in a 5% CO₂ environment for 24 h.

On the following day compound dilutions are made up in medium at twice their
5 desired final concentration in a clear round bottomed plate. All dilutions have a final DMSO concentration of 1%.

Once the dilution plate had been made up, controls and compounds were transferred to the assay plate (containing the cells) at 100µl /well in duplicate plates.

Exception: in the white (replicon) plate, no compound was added to wells A1 and A2

10 and 100µl of 1% DMSO was added to these instead. In the clear (Tox) plate, wells E12 & F12 only contained the DMSO control. Plates were then incubated at 37°C with 5% CO₂ for 72h.

At the end of the incubation time, the cells in the white plate were harvested by washing with 200 µl/ well of warm (37°C) PBS and lysed with 20 µl cell culture lysis
15 buffer (Promega). After 5 min incubation @ RT, luciferin solution was added to the luciferase assay buffer (LARb at 200µl per 10 ml LARb. The M injector of the microplate luminometer (Lmax, Molecular Devices) was primed with 4 x 300µl injections. Plate were inserted into the luminometer and 100 µl luciferase assay reagent was added by the injector on the luminometer. The signal was measured using a 1
20 second delay followed by a 4 second measurement programme. The IC₅₀, the concentration of the drug required for reducing the replicon level by 50% in relation to the untreated cell control value, can be calculated from the plot of the percentage reduction of the luciferase activity vs. drug concentration.

The clear plate was stained with 100µl 0.5% methylene blue in 50% ethanol at
25 RT for 1h, followed by solvation of the absorbed methylene blue in 100 µl per well of 1% lauroylsarcosine. Absorbance of the plate was measured on a microplate spectrophotometer (Molecular Devices) and the absorbance for each concentration of compound expressed as a proportion of the relative DMSO control. The TD₅₀, the concentration of drug required to reduce the total cell area by 50% relative to the
30 DMSO controls was calculated by plotting the absorbance at 620nm vs drug concentration.

Results are shown in the Table below.

Example No	replicon IC50	tox TD50
	μM	μM
1	<1	>32
2	1 to 10	25
3	>10	22
4	1 to 10	>33
5	1 to 10	50
6	1 to 10	>34
7	<1	49
8	1 to 10	>50
9	1 to 10	>31
10	1 to 10	>36
11	1 to 10	>30
12	1 to 10	46
13	1 to 10	>50
14	1 to 10	>50
15	1 to 10	>50
16	1 to 10	24
17	1 to 10	27


Example No	replicon IC50	tox TD50
	μM	μM
18	<1	10
19	1 to 10	11
20	1 to 10	23
21	1 to 10	30
22	1 to 10	>50
23	<1	16
24	<1	>50
25	<1	20
26	>10	46
27	1 to 10	>50
28	>10	>40
29	1 to 10	>50
30	1 to 10	32
31	1 to 10	30
32	1 to 10	30
33	1 to 10	36
34	<1	22

Example No	replicon IC50	tox TD50
	μM	μM
39	1 to 10	19
40	1 to 10	>50
41	>10	>50
42	<1	>50
43	<1	26
44	<1	22
45	1 to 10	>50
46	<1	42
47	<1	17
48	1 to 10	>50
49	1 to 10	>50
50	<1	18
51	1 to 10	35
52	1 to 10	36
53	1 to 10	15
54	<1	13.5
55	1 to 10	>50

Example No	replicon IC50	tox TD50
	μM	μM
56	<1	26
57	1 to 10	34
58	1 to 10	22
59	<1	57
60	<1	>50
61	1 to 10	>50
62	1 to 10	18
63	1 to 10	20
64	1 to 10	19
65	<1	22
66	<1	38
69	1 to 10	46
70	<1	32
71	<1	>50
72	<1	>50
73	<1	18
74	<1	29

CLAIMS

1. Use of pyrazolopyrimidine derivative of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in treating or
 5 preventing a flaviviridae infection,



wherein:

- R₁ is C₆-C₁₀ aryl, 5- to 10- membered heteroaryl, -(C₁-C₄ alkyl)-(C₆-C₁₀ aryl) or -(C₁-C₄ alkyl)-(5- to 10- membered heteroaryl);
 - R₂ is a C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heteroaryl or 5- to
 10 10- membered heterocyclyl moiety, said moiety being optionally fused to a C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclic ring; and
 - X is -NR', -NR'-CO-NR'', -NR'-L- or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C₁-C₆ alkyl group and L
 15 represents a C₁-C₆ alkylene group,
- the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, nitro, C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'-
 20 CO₂-R'', -CO₂R'', -COR''', -NR'-CO-R''', -CONR'R'', -SO₂NR'R'', -SO₂R''' and -O-(CH₂)_n-R''' substituents, wherein n is from 0 to 4, each R' is the same or different and is hydrogen or C₁-C₆ alkyl, each R'' is the same or different and is hydrogen, C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered
 25 heterocyclyl or 5- to 10- membered heteroaryl, and each R''' is the same or different and is C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl,
- the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents

being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl, C₁-C₄ hydroxyalkyl and C₁-C₄ haloalkyl groups.

2. Use according to claim 1, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents are unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, nitro, C₆-C₁₀ aryl, C₃-C₆ carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'[/]-CO₂-R''[/], -CO₂R''[/], -COR'''[/], -NR'[/]-CO-R'''[/], -CONR'[/]R''[/], -SO₂NR'[/]R''[/] and -SO₂R'''[/] substituents, wherein each R'[/] is the same or different and is hydrogen or C₁-C₆ alkyl, each R''[/] is the same or different and is hydrogen, C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl and each R'''[/] is the same or different and is C₁-C₆ alkyl, C₆-C₁₀ aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl.
3. Use according to claim 1, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents are unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl, -NR'[/]-CO₂-R''[/], -CO₂R''[/], -CO-R'''[/], -NR'[/]-CO-R'''[/], -CONR'[/]R''[/], -SO₂NR'[/]R''[/], -SO₂R'''[/] and -O-(CH₂)_n-R'''[/] substituents, wherein n is from 0 to 4, each R'[/] is the same or different and represents hydrogen or C₁-C₄ alkyl, each R''[/] is the same or different and represents hydrogen, C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, each R'''[/] is the same or different and represents C₁-C₄ alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, and each R'''[/] is the same or different and represents a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, the heteroaryl and heterocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C₁-C₄ alkyl and C₁-C₄ hydroxyalkyl groups.
4. Use according to claim 3, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R₁ and R₂ substituents are unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkyl, C₁-C₄ haloalkoxy, cyano, 5- to 6- membered heteroaryl, 5- to 6- membered

heterocyclyl, $-\text{NR}'-\text{CO}_2-\text{R}''$, $-\text{CO}_2\text{R}''$, $-\text{CO}-\text{R}'''$, $-\text{NR}'-\text{CO}-\text{R}'''$, $-\text{CONR}'\text{R}''$, $-\text{SO}_2\text{NR}'\text{R}''$ and $-\text{SO}_2\text{R}'''$ substituents, wherein each R' is the same or different and represents hydrogen or C_1 - C_4 alkyl, each R'' is the same or different and represents hydrogen, C_1 - C_4 alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, and each R''' is the same or different and represents C_1 - C_4 alkyl, a 5- or 6- membered heteroaryl group or a 5- or 6- membered heterocyclyl group, the heteroaryl and heterocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C_1 - C_4 alkyl and C_1 - C_4 hydroxyalkyl groups.

5. Use according to claim 1, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R_1 and R_2 substituents are unsubstituted or substituted by 1 or 2 unsubstituted substituents selected from halogen, C_1 - C_4 alkyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkoxy, cyano, 5- to 6- membered heteroaryl, 5- to 6- membered heterocyclyl, $-\text{CO}_2\text{R}'$, $-\text{CONR}'\text{R}''$, $-\text{NR}'-\text{COR}'''$, $-\text{SO}_2-\text{NR}'\text{R}'''$ and $-\text{O}-(\text{C}_1-\text{C}_2 \text{ alkyl})-\text{R}_i$ substituents, wherein each R' and R'' are the same or different and represent hydrogen or C_1 - C_4 alkyl, each R''' is the same or different and represents a C_1 - C_4 alkyl group, each R''' is the same or different and represents hydrogen, C_1 - C_4 alkyl or 5- to 6- membered heteroaryl and each R_i is the same or different and represents 5- to 6- membered heteroaryl.

6. Use according to any one of the preceding claims wherein R_1 is unsubstituted or substituted by 1, 2 or 3 substituents selected from C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halogen and C_1 - C_4 haloalkyl substituents.

7. Use according to any one of the preceding claims wherein R_1 is a phenyl group.

8. Use according to any one of the preceding claims wherein R_2 is a C_3 - C_6 carbocyclyl or 5- to 10- membered heterocyclyl group or is a C_6 - C_{10} aryl or 5- to 10- membered heteroaryl moiety which moiety is optionally fused to a C_3 - C_6 carbocyclyl group or to a phenyl ring.

9. Use according to any one of the preceding claims wherein R_2 is a phenyl or 5- to 6- membered heteroaryl moiety which is optionally fused to a phenyl or C_3 - C_6 cycloalkyl group.

5 10. Use according to any one of the preceding claims wherein X is $-NR'$ -, $-NR'-CO-NR''$ -, $-NR'-L$ - or $-NR'-CO-L$ -, wherein R' and R'' are the same or different and each represent hydrogen or a C_1 - C_4 alkyl group, and L represents a C_1 - C_4 alkylene group.

10 11. Use according to any one of the preceding claims, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R_2 substituent do not carry a $-CONR'R''$ substituent when X is $-NR'$ - and R_1 is an unsubstituted phenyl group.

12. Use according to claim 11, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R_1 and R_2 substituents do not carry a $-CONR'R''$ substituent.

15

13. Use according to claim 11, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R_1 and R_2 substituents do not carry an $-NR'-CO_2R''$, $-CO_2R''$, $-COR'''$, $-NR'-CO-R'''$, $-CONR'R''$ or $-SO_2-NR'R''$ substituent when X is $-NR'$ -.

20 14. Use according to claim 13, wherein the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in the R_1 and R_2 substituents do not carry an $-NR'-CO_2R''$, $-CO_2R''$, $-COR'''$, $-NR'-CO-R'''$, $-CONR'R''$ or $-SO_2-NR'R''$ substituent.

25 15. Use according to any one of the preceding claims, wherein the flaviviridae infection is a hepatitis C infection.

16. A product containing:


- 30 (a) a compound according to any one of claims 1 to 14;
(b) interferon and/or ribavirin; and
(c) a pharmaceutically acceptable carrier or diluant

for simultaneous, separate or sequential use in the treatment of the human or animal body.

17. A method of alleviating or reducing the incidence of a flaviviridae infection, as defined in claim 1 or 15, in a patient, which method comprises administering to said patient an effective amount of a pyrazolopyrimidine derivative of formula (I), as defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof.

5

18. A pharmaceutical composition comprising a pyrazolopyrimidine derivative of formula (I'), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluant or carrier,



10 wherein R₂ and X are as defined in any one of claims 1 to 14 and R₁ is a phenyl group which is unsubstituted or substituted by 1 or 2 substituents selected from C₁-C₄ alkyl, halogen and C₁-C₄ haloalkyl substituents.

19. A composition according to claim 18, wherein X in the formula (I') is -NR'-CO-
 15 NR''- or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent a C₁-C₆ alkyl group and L represents a C₁-C₆ alkylene group.

20. A pharmaceutical composition comprising (a) a compound of formula (I) as defined in any one of claims 1 to 14, a compound of formula (I') as defined in claim 18 or 19, or a pharmaceutically acceptable salt thereof, (b) interferon and/or ribavirin and
 20 (c) a pharmaceutically acceptable diluant or carrier.

21. A pyrazolopyrimidine derivative of formula (I'), as defined in claim 18 or 19, or a pharmaceutically acceptable salt thereof, for use in the treatment of the human or
 25 animal body.

22. A pyrazolopyrimidine derivative of formula (I'), as defined in claim 18 or 19, or a pharmaceutically acceptable salt thereof, provided that the compound of formula (I') is other than (1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(5,6,7,8-tetrahydro-naphthalen-1-yl)-amine, (2-Bromo-phenyl)-(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine, 1-Benzyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-(2,4-dimethyl-phenyl)-amine, [2-(4-Chloro-phenyl)-ethyl]-[1-(2,4-dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine and 4-Anilino-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine.

23. A compound according to claim 22, wherein R₂ in the formula (I') is other than an unsubstituted phenyl group.

24. 5-Amino-1-(2,4-dimethyl-phenyl)-1H-pyrazole-4-carbonitrile;
1-(2,4-Dimethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine;
1-(2-Bromo-phenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine;
4-Chloro-1-(2-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;
4-Chloro-1-(2,4-dichloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;
4-Chloro-1-(2-trifluoromethyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;
4-Chloro-1-(3-chloro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;
1-(4-Bromo-phenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine;
4-Chloro-1-(2,4-difluoro-phenyl)-1H-pyrazolo[3,4-d]pyrimidine;
4-Chloro-1-p-tolyl-1H-pyrazolo[3,4-d]pyrimidine; or
1-Benzyl-4-chloro-1H-pyrazolo[3,4-d]pyrimidine.

INTERNATIONAL SEARCH REPORT

In tional Application No
PC1/GB2004/004744

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/505 A61P31/12
//(C07D487/04, 239:00, 231:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94/13677 A (PFIZER INC.) 23 June 1994 (1994-06-23) cited in the application	18-23
A	claims 1-12	1-17
A	US 6 037 335 A (H. TAKASHIMA ET AL.) 14 March 2000 (2000-03-14) claims 1-7	1-24
A	DATABASE CAPLUS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002317940 retrieved from STN Database accession no. 1994:400268 abstract -/--	1-24

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

16 February 2005

Date of mailing of the international search report

01/03/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Herz, C

INTERNATIONAL SEARCH REPORT

In **onal Application No**
PCT/GB2004/004744

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>& T. YOKOTA ET AL.: "Inhibitory effects of acyclic nucleoside phosphonate analogs on hepatitis B" ANTIVIRAL CHEMISTRY AND CHEMOTHERAPY, vol. 5, no. 2, 1994, pages 57-63,</p> <p>-----</p> <p>PATENT ABSTRACTS OF JAPAN vol. 1995, no. 06, 31 July 1995 (1995-07-31) & JP 07 070159 A (MITSUBISHI CHEM. CORP.), 14 March 1995 (1995-03-14) abstract</p> <p>-----</p>	1-24
A	<p>P. SCHMIDT, J. DRUEY: "Heilmittelchemische Untersuchungen in der heterocyclischen Reihe. Pyrazolo-(3,4-d)-pyrimidine" HELVETICA CHIMICA ACTA, vol. 39, 1956, pages 986-991, XP009044079 table 1</p> <p>-----</p>	1-24

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB2004/004744

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9413677	A	23-06-1994	AT 195738 T	15-09-2000
			AU 680226 B2	24-07-1997
			AU 5728194 A	04-07-1994
			BR 9307648 A	25-05-1999
			CA 2150709 A1	23-06-1994
			CN 1094048 A ,C	26-10-1994
			CZ 9501586 A3	15-11-1995
			DE 69329296 D1	28-09-2000
			DE 69329296 T2	28-12-2000
			DK 674642 T3	18-09-2000
			EG 20273 A	31-05-1998
			EP 0674642 A1	04-10-1995
			ES 2150482 T3	01-12-2000
			FI 935675 A	18-06-1994
			GR 3034507 T3	29-12-2000
			HU 70426 A2	30-10-1995
			IL 107944 A	06-12-2000
			JP 2862375 B2	03-03-1999
			JP 7509728 T	26-10-1995
			KR 167395 B1	15-01-1999
			KR 225720 B1	15-10-1999
			NO 952399 A	16-08-1995
			NZ 259114 A	24-03-1997
			PL 309359 A1	02-10-1995
			PT 674642 T	31-01-2001
			RU 2124016 C1	27-12-1998
			TW 444018 B	01-07-2001
			WO 9413677 A1	23-06-1994
			US 6218397 B1	17-04-2001
			ZA 9309405 A	15-06-1995
US 6037335	A	14-03-2000	AT 199906 T	15-04-2001
			CA 2126601 A1	30-12-1994
			CN 1106017 A ,C	02-08-1995
			DE 69426904 D1	26-04-2001
			DE 69426904 T2	11-10-2001
			EP 0632048 A1	04-01-1995
			JP 3580377 B2	20-10-2004
			JP 7070159 A	14-03-1995
JP 07070159	A	14-03-1995	JP 3580377 B2	20-10-2004
			AT 199906 T	15-04-2001
			CA 2126601 A1	30-12-1994
			CN 1106017 A ,C	02-08-1995
			DE 69426904 D1	26-04-2001
			DE 69426904 T2	11-10-2001
			EP 0632048 A1	04-01-1995
			US 6037335 A	14-03-2000